前往化源商城

68-41-7 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: SNCA-p-activity-luciferase
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION

1; Cells; 4 uL; Dispense 1500 HEK-293-SNCA-luc cells/well into Greiner 1536-well white / solid bottom tissue culture treated plate. The plate was covered with metal lids with gas-exchange holes.
2; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
3; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array. The plate was covered with metal lids with gas-exchange holes.
4; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
5; Dispense; 1 uL; Dispense Gly-Phe-7-amino-4-trifluoromethylcoumarin (GF-AFC, prepared at 125 uM in PBS) was added. The plate was covered with metal lids with gas-exchange holes.
6; Incubate; 30 min; Incubate at 37C, 5% CO2.
7; Detector; Fluorescence; Measure fluorescence with ViewLux microplate reader (PerkinElmer) equipped with 405/10 excitation and 540/25 emission filters.
8; Dispense; 3 uL; Dispense ONE-Glo (PerkinElmer) lucifase detection reagent was added to each well. Plates were covered with metal lids with gas-exchange holes.
9; Incubate; 15 min; Incubate at room temperature.
10; Detector; Luminescence; Measure luminescence with ViewLux microplate reader (PerkinElmer) equipped with clear filters.

NOTES (numbers refer to sequence above)
1; HEK-293-SNCA-luc were cultured and suspended in phenol-red free DMEM (4.5 g/L glucose, 25 mM HEPES, cat #21063 (Thermo)).
3; Compounds were added to the assay plate in an 11-point intra plate dose response, 1:3 titration in DMSO with a final concentration range of xxx - yyy uM. Vehicle-only plates, with DMSO being pin-transferred to every well, were inserted at the beginning of screening runs to confirm expected assay performance. Activity was normalized to wells containing medium only (-100% activity, full inhibition) and SNCA-luc cells treated with DMSO vehicle control (0% activity), contained on the same plate as test samples.
10; Signals were analyzed, and dose-response curves were fit using the Hill equation. Compounds in curve classes -1.1, -1.2, -2.1, -2.2 in the SNCA-luc assay were considered active. Compounds were eliminated from further consideration if also active (curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4) in the GF-AFC cytotoxicity assay.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0001896372 uMActivity at 0.0004510146 uMActivity at 0.0007501981 uMActivity at 0.0009728036 uMActivity at 0.00288 uMActivity at 0.00508 uMActivity at 0.00871 uMActivity at 0.015 uMActivity at 0.026 uMActivity at 0.053 uMActivity at 0.079 uMActivity at 0.232 uMActivity at 0.457 uMActivity at 0.692 uMActivity at 1.068 uMActivity at 2.292 uMActivity at 3.859 uMActivity at 11.39 uMActivity at 17.02 uMActivity at 25.62 uMActivity at 57.25 uMActivity at 87.55 uMActivity at 183.4 uMActivity at 286.0 uMCompound QC
Inactive0-6.754.95490.97270.090117.540 0 0 18.940815.9527-1.59161.49698.9408QC'd by Sytravon
Inactive0-5.34.0950.99965.5-7.782340 0 0 1-11.1081-7.5736-7.73535.034-11.1081QC'd by Sytravon
Inactive0-5.154.95490.907-15.92079.540 0 0 117.87255.287413.9021-13.683917.8725QC'd by Sytravon
Activator35.481346.40950Single point of activity-4.452.5884145.9404-0.469131 0 0 035.59340.1678-0.39091.93335.593QC'd by Sytravon
Activator39.810772.26460Single point of activity-4.44.95490.951568.1912-4.073330 0 0 058.01175.8738-9.2278-8.522458.0117QC'd by Sytravon
Activator14.125445.33190Partial curve; partial efficacy; poor fit-4.852.40640.998240.7728-4.55912.41 0 0 040.0933-24.9557-3.884511.525440.0933QC'd by Sytravon
Inactive0-5.754.95490.9291-20.608633.154541 0 0 0-12.846445.456928.2161-28.42-12.8464QC'd by Sytravon
Inactive0-4.354.95490.855-24.2184-0.540 0 0 0-18.932-3.6477-2.4094.988-18.932QC'd by Sytravon
Inactive0-4.73.62720.862515-8.552340 0 0 014.477-2.951-13.7936-5.964614.477QC'd by Sytravon
Inactive0-6.74.95490.66373-16.86440 0 0 08.8169-15.726.3794-6.35998.8169QC'd by Sytravon
Inactive0-4.752.40640.999921.5-2.410141 0 0 020.218433.3778-2.42513.577120.2184QC'd by Sytravon
Inactive0-4.44.95490.81172.5-8.34540 0 0 01.096-8.966-5.5054-11.12091.096QC'd by Sytravon
Activator39.810738.79450Single point of activity-4.44.95490.624141.75572.961230 0 0 036.203921.355-6.3904-4.532536.2039QC'd by Sytravon
Inactive0-6.054.0950.9994-6.05182040 0 0 120.515619.73771.4122-6.293220.5156QC'd by Sytravon
Inactive0-5.24.095110.5-10.168341 0 0 1-15.988436.1362-10.14028.7939-15.9884QC'd by Sytravon
Inactive0-6.51.39050.9999-24.2410.274540 0 0 1-5.5981-4.3546-20.7587-23.9509-5.5981QC'd by Sytravon
Inactive0-6.84.95490.711-2.44592140 0 0 0-3.345317.3219-9.95495.5495-3.3453QC'd by Sytravon
Activator39.810747.8090Partial curve; partial efficacy; poor fit-4.44.95490.521250.23992.43092.40 0 0 043.472230.2363-10.9855-11.514343.4722QC'd by Sytravon
Activator22.387275.50810Partial curve; high efficacy; poor fit-4.651.96730.982996.532421.02432.30 0 0 086.498526.093216.336536.261386.4985QC'd by Sytravon
Inactive0-6.84.95490.7429-1-13.073840 0 0 01.8063-11.31150.8702-5.17571.8063QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: CYP273
Protocol: Tox21 Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a BioRaptr Flying Reagent Dispenser (FRD, Beckman Coulter, Brea, CA). Compounds dissolved in DMSO and positive control (furafyllline) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000075213 uM-Replicate_1Activity at 0.0000171744 uM-Replicate_1Activity at 0.0000689059 uM-Replicate_1Activity at 0.0001619730 uM-Replicate_1Activity at 0.0003751800 uM-Replicate_1Activity at 0.0007781017 uM-Replicate_1Activity at 0.00212 uM-Replicate_1Activity at 0.00657 uM-Replicate_1Activity at 0.017 uM-Replicate_1Activity at 0.038 uM-Replicate_1Activity at 0.085 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.435 uM-Replicate_1Activity at 1.330 uM-Replicate_1Activity at 4.074 uM-Replicate_1Activity at 10.46 uM-Replicate_1Activity at 23.64 uM-Replicate_1Activity at 52.95 uM-Replicate_1Activity at 115.2 uM-Replicate_1Activity at 299.6 uM-Replicate_1Activity at 1087.9 uM-Replicate_1Activity at 2306.0 uM-Replicate_1Activity at 5157.0 uM-Replicate_1Activity at 11530.0 uM-Replicate_1Activity at 25780.0 uM-Replicate_1Activity at 57660.0 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2
Inactive0004-3.5643-2.3504-2.9312-2.3657-2.8224-2.60180.03942.8539-0.9099-0.8614-3.0049-2.5808-0.7-3.5643QC'd by SIGMAInactive0
Inactive0004-4.9449-1.1401-4.88281.72781.7167-2.1117-5.69640.39330.89390.1314-2.73353.195-4.9521-4.9449QC'd by SIGMAInactive0
Inactive00042.7107-2.18841.39851.45820.7693-2.47871.522.89860.9702-0.02532.12932.77661.5392.7107QC'd by EnamineInactive0
Inactive0004-2.1522-2.3143-3.894-2.36983.0635-2.9724-0.6981.807-0.3874-2.23870.0851-4.19653.0171-2.1522QC'd by SIGMAInactive0
Inactive0-4.34892.25260.8543-15.2749-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.3957-1.8486-1.8251-1.3415-0.2999-5.8043-1.46250.1520.0394-2.6869-2.4228-2.2664-9.6519-14.3957QC'd by SIGMAInactive0-4.09892.18760.881
Inactive0-4.39891.34430.8661-18.2112-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-16.0093-2.34660.81450.3878-0.5249-2.2045-0.0596-0.3675-2.1137-2.5302-0.6582-8.8446-8.7305-16.0093QC'd by AcrosInactive0-4.19891.62660.9372
Inactive0-4.37131.3310.7782-33.4439-3.50340 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.5366-4.0189-0.7745-2.4487-0.7353-13.4714-1.9963-2.0808-1.5803-2.9931-5.0804-13.0346-7.2628-16.8143-29.5366QC'd by LightBiologicalsInactive0-4.37131.22210.9463
Inactive0-4.14891.62660.9461-28.1716-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-20.143-1.7608-0.23880.22480.5264-2.4986-0.1313-2.2365-0.2423-3.4362-3.0971-3.2181-11.2156-20.143QC'd by EnamineInhibitor79.640731.491610Partial curve; partial efficacy; poor fit-4.09892.58840.988
Inhibitor79.640737.878410Partial curve; partial efficacy; poor fit-4.09892.33320.6037-41.3784-3.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.14860.0477-0.2424-0.1109-17.1482-2.60430.09871.3021-8.8121-0.6811-2.6079-6.0005-11.8578-31.1486QC'd by LightBiologicalsInhibitor70.979933.811310Partial curve; partial efficacy; poor fit-4.14891.47870.9532
Inactive0-4.14891.3310.6595-35.6335-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-26.36121.8269-1.26512.0528-1.3342-1.1508-1.3078-0.329-8.12350.9213-0.3901-8.3475-13.4823-26.3612QC'd by LightBiologicalsInhibitor63.260940.716221Partial curve; partial efficacy-4.19891.55790.9889
Inhibitor31.7055100.219240Partial curve; high efficacy-4.49891.41630.9793-102.2947-2.0755-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.79751.59931.9578-0.4182-5.9156-12.3257-6.81250.6301-0.9357-7.8675-21.9718-39.1747-68.2733-88.7975QC'd by SIGMAInhibitor28.2576108.402740Partial curve; high efficacy-4.54891.24750.9984
Inactive0-4.44891.53860.9285-23.7863140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-21.48852.58192.144-0.92281.57780.3813-0.7273-0.01780.48032.4385-0.728-9.9293-11.8247-21.4885QC'd by SIGMAInactive0-4.39891.62590.9598
Inhibitor9.333739.896721Complete curve; partial efficacy-5.02992.04370.9899-39.89670-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-36.3129-0.2423-0.4463-0.29990.64780.36361.006-0.49871.2825-1.1546-7.8589-17.895-35.8398-36.3129QC'd by LightBiologicalsInhibitor11.750456.388421Partial curve; partial efficacy-4.92991.1110.9845
Inhibitor31.7055101.457340Partial curve; high efficacy-4.49891.1110.9982-102.7597-1.3024-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-82.349-1.7206-3.1014-1.0307-0.462-0.0614-0.5481-3.1286-4.6801-13.1432-23.5612-42.1146-67.192-82.349QC'd by SIGMAInhibitor25.184689.509140Partial curve; high efficacy-4.59891.37230.9943
Inactive0-4.39891.37230.9408-30.7143-1.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-27.2619-3.9038-4.25970.95220.2767-0.086-3.7725-0.0863-0.3476-4.4856-5.6587-11.4378-17.5999-27.2619QC'd by EnamineInactive0-4.39891.37230.9104
Inhibitor0.0291.537495Complete curve; high efficacy-7.69891.210.9985-95.5053-3.9679-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.9758-10.1145-26.2532-42.3865-67.4835-79.9456-90.8539-91.593-94.2489-95.4721-96.0956-96.1267-97.0582-96.9758QC'd by SIGMAInhibitor0.141694.840291Complete curve; high efficacy-6.84891.210.9987
Inhibitor70.979957.401421Partial curve; partial efficacy-4.14891.46410.9678-60.4859-3.0846-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-45.8227-1.5241-1.1304-2.119-3.4583-2.7138-4.9163-1.3699-5.0741-7.7268-8.2608-10.3758-24.1789-45.8227QC'd by TCIInhibitor63.260959.370621Partial curve; partial efficacy-4.19891.82650.9826
Inhibitor31.705588.458340Partial curve; high efficacy-4.49891.24750.9907-90.0614-1.6031-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-73.0646-2.1792-0.7242-0.9217-2.0267-1.1711-1.4022-1.5555-4.0648-12.1704-19.1709-32.2561-64.0802-73.0646QC'd by SIGMAInhibitor31.705586.838540Partial curve; high efficacy-4.49891.1110.9934
Inhibitor7.09899.944883Complete curve; high efficacy-5.14891.34430.9949-102.6257-2.681-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-98.8687-2.2636-1.9377-0.2674-0.3864-3.2139-8.5636-4.0834-14.5383-36.543-60.2337-91.3595-96.848-98.8687QC'd by TCIInhibitor5.638199.072784Complete curve; high efficacy-5.24891.62660.998
Inhibitor14.162399.52242Partial curve; high efficacy-4.84890.70.9894-100.6417-1.1197-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-88.2822-1.4919-2.9847-0.2649-1.6478-3.8502-2.8959-7.6423-18.6375-36.1235-44.1844-53.91-71.7844-88.2822QC'd by SIGMAInhibitor17.829395.774281Complete curve; high efficacy-4.74891.210.9995
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_OPM1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.011890.089787Complete curve; high efficacy-7.92922.47290.96942.5966132.6862-1.10 0 0 0 0 0 0 0 0 0 057.466123.2938140.8388112.24160.901644.089639.767736.478540.20639.176941.461857.466QC'd by ChemAxon
Cytotoxic0.417675.850987Complete curve; high efficacy-6.37921.53860.949872.4265148.2774-1.10 0 0 0 0 0 0 0 0 0 061.5626139.2774158.5971143.0204144.9664147.8567136.015191.815692.950575.674674.676861.5626QC'd by JohnsHopkins
Cytotoxic0.148294.419287Complete curve; high efficacy-6.82921.10.951759.4372153.8564-1.10 0 0 0 0 0 0 0 0 0 055.0456164.8354134.704151.2303143.6834134.761595.648470.062167.305676.105555.692455.0456QC'd by Selleck
Cytotoxic0.166394.102386Complete curve; high efficacy-6.77922.72020.972950.0751144.1775-1.10 0 0 0 0 0 0 0 0 0 056.0568132.0924142.9387160.1371137.1338142.289985.893148.200245.041752.603354.183256.0568QC'd by ACC
Cytotoxic0.0332121.075286Complete curve; high efficacy-7.479210.984142.1192163.1944-1.10 0 0 0 0 0 0 0 0 0 035.7472158.2854158.4708139.505123.340671.574165.258955.071850.086742.178237.195535.7472QC'd by Selleck
Cytotoxic0.742778.671685Complete curve; high efficacy-6.12921.88510.983463.6148142.2865-1.10 0 0 0 0 0 0 0 0 0 058.2475142.1116146.4992135.5304145.8795136.7066141.0466113.833174.38665.128871.886858.2475QC'd by Tocris
Cytotoxic0.833386.219185Complete curve; high efficacy-6.079210.930267.549153.7681-1.10 0 0 0 0 0 0 0 0 0 069.8532158.4753142.7847153.7541141.7507166.925141.693105.2958104.667477.221776.165269.8532QC'd by Tocris
Cytotoxic3.722164.493585Complete curve; high efficacy-5.42924.95490.792112.0642176.5577-1.10 0 0 0 0 0 0 0 0 0 089.6942158.9633166.2699180.3984167.1951174.9654191.2964181.3214193.1909122.0222135.538889.6942QC'd by Tocris
Cytotoxic0.0526123.236885Complete curve; high efficacy-7.27920.60.972433.4065156.6433-1.10 0 0 0 0 0 0 0 0 0 035.7651153.6951126.1364142.4363103.249192.595173.147860.614343.388740.031337.882135.7651QC'd by Tocris
Cytotoxic0.006677.526284Complete curve; high efficacy-8.17920.80.975321.696999.2231-1.10 0 0 0 0 0 0 0 0 0 013.262791.55276.413756.561242.193434.028331.180927.350626.077820.634320.214413.2627QC'd by Tocris
Cytotoxic0.5258123.459984Complete curve; high efficacy-6.27921.39870.968242.1223165.5821-1.10 0 0 0 0 0 0 0 0 0 025.7016164.86160.7689152.0063170.1205168.2257149.303488.213874.069651.798249.790125.7016QC'd by JohnsHopkins
Cytotoxic1.865582.375984Complete curve; high efficacy-5.72922.33320.929161.702144.078-1.10 0 0 0 0 0 0 0 0 0 051.7606136.01140.2451152.6106148.0124143.6336147.0904134.4052111.284254.479484.371251.7606QC'd by Selleck
Cytotoxic2.3485101.924784Complete curve; high efficacy-5.62920.60.955871.9549173.8795-1.10 0 0 0 0 0 0 0 0 0 091.649176.6761171.0851177.7813159.9071159.3009150.4576153.7054126.8633116.427184.815491.649QC'd by SynKinase
Cytotoxic0.018790.923784Complete curve; high efficacy-7.72920.70.995926.7347117.6584-1.10 0 0 0 0 0 0 0 0 0 029.5723109.5774101.759683.749673.379952.652141.5735.435430.241226.675925.387729.5723QC'd by Microsource
Cytotoxic0.0132127.373583Complete curve; high efficacy-7.87920.70.972217.3385144.712-1.10 0 0 0 0 0 0 0 0 0 033.7384132.8301113.247589.341775.717555.400227.741422.107814.440214.011616.778533.7384QC'd by Tocris
Cytotoxic3.722186.014283Complete curve; high efficacy-5.42921.210.972165.5416151.5558-1.10 0 0 0 0 0 0 0 0 0 066.7748154.8648146.5307153.6238147.9405153.7843144.2907154.4262119.8728100.256583.011166.7748QC'd by Tocris
Cytotoxic0.3722105.789883Complete curve; high efficacy-6.42922.84730.98436.148141.9378-1.10 0 0 0 0 0 0 0 0 0 022.8052141.9378142.9518145.1156141.0583137.6217130.508557.913351.266941.388233.000722.8052QC'd by JohnsHopkins
Cytotoxic1.6626102.314483Complete curve; high efficacy-5.779210.924240.9668143.2813-1.10 0 0 0 0 0 0 0 0 0 047.0105152.3961124.7264140.9824142.6059141.9566147.0368112.397281.287385.089138.460247.0105QC'd by Microsource
Cytotoxic0.0118140.01383Complete curve; high efficacy-7.92922.58840.998217.9926158.0057-1.10 0 0 0 0 0 0 0 0 0 014.8749156.5885154.4434130.9445.126815.310417.374218.814419.415621.188621.270814.8749QC'd by Selleck
Cytotoxic0.4686118.608983Complete curve; high efficacy-6.32921.85790.987228.1061146.7151-1.10 0 0 0 0 0 0 0 0 0 027.0205138.0525155.3457144.6536140.3247148.8544132.291370.355346.41333.133522.075327.0205QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Mycobacterium tuberculosis
External ID: CHEMBL3123524
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2014
Volume: 74
First Page: 664
Last Page: 670
DOI: 10.1016/j.ejmech.2013.09.061

Target ChEMBL ID: CHEMBL360
ChEMBL Target Name: Mycobacterium tuberculosis
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
IC90=74.96ug.mL-1Outside typical range
IC50=37.35ug.mL-1
IC90=0.29ug.mL-1
IC50=0.18ug.mL-1
IC90=13.49ug.mL-1
IC50=12.47ug.mL-1
IC90=32.79ug.mL-1
IC50<1.56ug.mL-1
IC90=0.08ug.mL-1
IC50=0.07ug.mL-1
IC90=0.02ug.mL-1
IC50=0.02ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-OC1MY5-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.016675.705499Complete curve; high efficacy-7.77921.62590.8287113.3664189.0718-1.10 0 0 0 0 0 0 0 0 0 076.415189.0718184.1323176.4162143.7765121.3848112.8196136.1769124.1622121.4205110.84976.415QC'd by SigmaAldrich
Cytotoxic0.014878.323895Complete curve; high efficacy-7.82921.88510.884990.161168.4848-1.10 0 0 0 0 0 0 0 0 0 067.4943179.706152.1469156.7226115.95190.887181.242794.0684108.643892.5891100.356267.4943QC'd by BIOMOL
Cytotoxic0.0093193.289593Complete curve; high efficacy-8.02920.50.866672.6851265.9745-1.10 0 0 0 0 0 0 0 0 0 0105.1458244.5929174.7663172.838154.9069132.1222117.372990.589987.865585.670530.7772105.1458QC'd by Microsource
Cytotoxic0.0021162.783989Complete curve; high efficacy-8.67922.25260.909541.4972204.2812-1.10 0 0 0 0 0 0 0 0 0 016.0569187.9512112.283154.611932.400643.04248.563547.468974.45340.548125.593516.0569QC'd by Tocris
Cytotoxic0.0037168.183989Complete curve; high efficacy-8.42921.98870.95444.8326213.0165-1.10 0 0 0 0 0 0 0 0 0 016.7704206.3802163.409786.454636.022349.839739.359743.293852.688461.372857.854816.7704QC'd by Waterstone
Cytotoxic0.0469148.810689Complete curve; high efficacy-7.32922.40640.8561.7336210.5442-1.10 0 0 0 0 0 0 0 0 0 08.2046222.3206202.2319203.978192.1974118.262335.92446.047760.9187116.720798.87498.2046QC'd by ChemAxon
Cytotoxic0.0026113.270989Complete curve; high efficacy-8.57923.1320.897742.9988156.2697-1.10 0 0 0 0 0 0 0 0 0 021.2361152.3367113.413840.593638.127740.362443.602334.137943.871364.736864.064821.2361QC'd by Tocris
Cytotoxic0.0017114.495389Complete curve; high efficacy-8.77924.0950.841643.8532158.3484-1.10 0 0 0 0 0 0 0 0 0 014.1898152.803967.85254.519352.359357.345849.82462.059347.505430.836728.465514.1898QC'd by Selleck
Cytotoxic0.002672.734289Complete curve; high efficacy-8.57922.72020.907441.83114.5643-1.10 0 0 0 0 0 0 0 0 0 049.3766112.187583.595146.53530.954733.435532.312943.245244.089344.797856.003549.3766QC'd by Microsource
Cytotoxic0.0743128.224189Complete curve; high efficacy-7.12920.30.807365.0905193.3146-1.10 0 0 0 0 0 0 0 0 0 071.5247186.4209158.6743129.1227120.8146138.5824133.4969104.1228120.2992101.960377.775671.5247QC'd by Tocris
Cytotoxic0.0662125.720489Complete curve; high efficacy-7.17921.82650.971967.5385193.259-1.10 0 0 0 0 0 0 0 0 0 052.5197186.6163181.5655200.1337192.1342128.241283.363287.409864.631570.685465.116152.5197QC'd by SantaCruz Bio
Cytotoxic0.661978.285988Complete curve; high efficacy-6.17921.88510.946996.3016174.5875-1.10 0 0 0 0 0 0 0 0 0 0101.3711171.7651176.8613184.4702181.7039154.2237171.0284143.1726100.579190.9185104.0348101.3711QC'd by BIOMOL
Cytotoxic0.0935125.731288Complete curve; high efficacy-7.02923.990.970262.9518188.683-1.10 0 0 0 0 0 0 0 0 0 071.3789173.2237176.4213202.4283200.5745169.056972.067947.835455.511865.182873.840471.3789QC'd by Selleck
Cytotoxic0.0743119.127488Complete curve; high efficacy-7.12920.70.98858.8412177.9686-1.10 0 0 0 0 0 0 0 0 0 065.4007172.7284171.0856155.1599146.3776116.585999.779291.984365.419864.002856.279365.4007QC'd by Axon Medchem
Cytotoxic0.3317103.910288Complete curve; high efficacy-6.47920.30.843677.4858181.396-1.10 0 0 0 0 0 0 0 0 0 0101.3477161.302177.473153.8803133.2684139.1275144.3925135.8497117.608691.5334104.8313101.3477QC'd by Tocris
Cytotoxic0.1321123.71788Complete curve; high efficacy-6.879210.962367.9127191.6297-1.10 0 0 0 0 0 0 0 0 0 045.8939178.5371199.9241184.0193181.5655149.5884112.02994.762981.731373.616983.205245.8939QC'd by Microsource
Cytotoxic0.0066144.59188Complete curve; high efficacy-8.17922.72020.931843.5813188.1723-1.10 0 0 0 0 0 0 0 0 0 07.9675169.8483200.8523105.256949.605442.518545.303152.145650.632956.794649.51437.9675QC'd by SIGMA
Cytotoxic0.935111.476387Complete curve; high efficacy-6.02921.46410.907288.9886200.4649-1.10 0 0 0 0 0 0 0 0 0 065.9282174.089200.6763211.7975212.4609203.6327185.8171171.8065108.7421105.1811115.181865.9282QC'd by Selleck
Cytotoxic0.0118148.747387Complete curve; high efficacy-7.92921.88510.914741.9403190.6876-1.10 0 0 0 0 0 0 0 0 0 08.0822198.2962171.9006154.032174.692245.681859.094162.628163.424350.903813.29568.0822QC'd by Selleck
Cytotoxic1.662684.625787Complete curve; high efficacy-5.77922.72020.9593106.2986190.9242-1.10 1 0 0 0 0 0 0 0 0 0104.8088197.9176147.6744188.5439182.4788196.4457175.6724199.742148.305107.0547110.4851104.8088QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:Burkholderia multivorans
External ID: HMS1625
Protocol: The fix-reporter plasmid was conjugated into this strain which the stably integrates into the chromosome using the mini-Tn7 system (PMID: 15908923). This plasmid consists of the fixK promoter, which is a target of the fixLJ pathway driving expression of GFP.
The day before screen an overnight culture of B. multivorans strain VC7102, with fix reporter, is set up in tryptic soy broth (TSB) at 37 degrees C with shaking. The day of the screen the overnight culture is diluted 1:100 in fresh tryptic soy broth.
The day of the screen, 30 microL of tryptic soy broth (TSB) is pipetted into columns 1-22 of a 384-well plate (Corning 3764) using the Combi multidrop dispenser. To column 24, 30 microL of TSB containing 78 microM of Benserazide TSB is added for a positive control. To column 23, 30 microL of TSB containing with DMSO (0.078% v/v in TSB) is added for a negative control. 300 nL of each compound are pin-transferred to each plate. For every compound plate 2 replicate assay plates are set up. 30 microL of the 1:100 diluted-B. multivorans strain VC7102 is added to each well using the Combi. Initial OD600 and GFP are measured using the PerkinElmer EnVision. Plates are stacked 5 high, covered with lids and incubated at 37 degrees C overnight (~18 h).
The following day, assay plates are read using a PerkinElmer EnVision (600 nm filter and GFP).
Positive control: Benserazide 39 microM in column 24 (No positive control was used for plates 2089 & 2090; Plates 2091-2093: columns 1 & 24)
Negative control: DMSO 300 nL/well in column 23 (For plates 2089 & 2090 negative controls were located in columns 2 & 24; plates 2091-2093: columns 2 & 23)
Comment: Analysis method:
For each compound well, the initial GFP value was subtracted from overnight GFP value to calculate the deltaGFP. The mean and standard deviation of the negative control wells deltaGFP (column 23) on both replicate plates was calculated. Wells with replicate average deltaGFP at least 3 standard deviations above the plate negative control deltaGFP average were scored as potential positives.

To determine activity scores, Z-scores were calculated for each replicate separately based on the replicate negative control deltaGFP plate average and standard deviation. The replicate average deltaGFP Z-scores were used for activity scores, with activity score of 100 set to Z-score = 4 and activity score = 0 (no activity) set to Z-score = 0. Z-scores > 4 were considered activity score = 100, and Z-scores < 0 were considered activity score = 0.
Avg_deltaGFP_Z-scoreAbsorbance_T0_AGFP_T0_AAbsorbance_T0_BGFP_T0_BAbsorbance_AGFP_AAbsorbance_BGFP_BdeltaGFP_AdeltaGFP_BAvg_deltaGFPdeltaGFP_A_Z-scoredeltaGFP_B_Z-score
-1.270.05825403560.05725477650.32326537670.3242670642113411122877118144-1.02538-1.51489
0.670.0624266120.0624127100.33225889350.33425870491623231743391683310.3877340.95318
-0.330.05925207730.05925090750.35426732820.3532672667152509163592158050-0.303321-0.354548
10.05924689030.0624661270.34126393810.34326573121704781911851808320.7401411.26456
0.740.10620472210.10720465420.56826607620.57126491096135416025676080540.5436960.932316
-0.660.09221234000.09121483410.52927175620.5272686607594162538266566214-0.115128-1.20669
-2.80.08421991470.08622312650.51327273860.512708166528239476901502570-2.3563-3.24802
-1.960.1121445580.10921539230.526876750.4922666280543117512357527737-1.8505-2.06856
-1.140.10420993670.10121425170.52326817780.5182664243582411521726552068-0.514625-1.7569
-1.270.0621639510.0621890320.47927247140.4792724846560763535814548288-1.25059-1.28825
0.440.11220635890.1121021270.54826852200.53626783436216315762165989240.8187310.0557383
-2.910.0821580040.07921702680.45726695940.4572657682511590487414499502-2.92231-2.8983
-0.490.09520760050.09621319850.52626668050.5242683829590800551844571322-0.229425-0.755007
-0.90.06220905540.06221416370.49726735090.4912677205582955535568559262-0.496131-1.29644
-0.250.11620795900.11521215660.52426775490.52526804075979595588415784000.0139578-0.522249
-2.520.06222558760.06122872190.51327838280.5092781307527952494088511020-2.36606-2.67629
-0.990.06521568750.06421851480.51427183540.5142737090561479551942556710-1.22625-0.751747
0.20.07622487490.07422362870.49828542360.49428440086054876077216066040.425044-0.0214336
-0.390.05921551930.06121585430.5327397010.5262750103584508591560588034-0.243403-0.538384
2.080.0821516730.07921560070.52828023590.52528361806506866801736654301.865212.29612
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-KMS_34-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.041888.877985Complete curve; high efficacy-7.37921.210.83931.4966120.3746-1.10 0 0 0 0 0 0 0 0 0 07.7124132.8926100.448796.9022107.952767.422923.232138.254730.074155.763343.34537.7124QC'd by ChemAxon
Cytotoxic0.0148116.450385Complete curve; high efficacy-7.82920.40.883227.623144.0733-1.10 0 0 0 0 0 0 0 0 0 023.9089133.149384.985690.676488.203880.547548.934346.794939.846148.370238.326523.9089QC'd by Tocris
Cytotoxic0.00363.507484Complete curve; high efficacy-8.52921.24750.846222.061585.5689-1.10 0 0 0 0 0 0 0 0 0 04.685578.444856.901238.37827.125924.86230.850833.175427.356122.258211.85044.6855QC'd by AG Scientific
Cytotoxic0.066281.534784Complete curve; high efficacy-7.17920.50.935226.2812107.8158-1.10 0 0 0 0 0 0 0 0 0 041.7013104.6491.691185.710374.992566.250263.828947.143640.11632.645316.398141.7013QC'd by Microsource
Cytotoxic0.005388.857983Complete curve; high efficacy-8.27920.70.918715.3166104.1745-1.10 0 0 0 0 0 0 0 0 0 017.273995.7755.043766.176737.487330.62723.923816.028919.552917.45899.815517.2739QC'd by Toronto Research
Cytotoxic0.209387.781383Complete curve; high efficacy-6.67923.06540.98628.7833116.5646-1.10 0 0 0 0 0 0 0 0 0 028.0348105.4018124.2663111.216120.9286117.829382.793730.938430.822427.522130.01228.0348QC'd by ACC
Cytotoxic0.016684.33283Complete curve; high efficacy-7.77922.72020.984217.1644101.4964-1.10 0 0 0 0 0 0 0 0 0 016.809492.1572111.714893.822544.879723.29116.702114.931216.05218.314117.449816.8094QC'd by ChemAxon
Cytotoxic0.037278.620483Complete curve; high efficacy-7.42922.58840.984618.797997.4182-1.10 0 0 0 0 0 0 0 0 0 012.888592.420695.8169102.935482.036534.503824.164219.157513.771216.322226.468312.8885QC'd by Selleck
Cytotoxic1.04996.497783Complete curve; high efficacy-5.97920.50.957536.2422132.7399-1.10 0 0 0 0 0 0 0 0 0 054.2766130.3979127.8742134.2077109.0067109.1952107.713199.92678.571159.936952.628454.2766QC'd by LINCS
Cytotoxic0.0469113.5983Complete curve; high efficacy-7.32921.92820.977620.8655134.4556-1.10 0 0 0 0 0 0 0 0 0 021.4008136.3735118.7418147.5619108.852467.204221.009224.201124.538819.698820.300321.4008QC'd by Tocris
Cytotoxic0.0059134.11483Complete curve; high efficacy-8.22920.90.958214.3732148.4872-1.10 0 0 0 0 0 0 0 0 0 07.7187135.6994.255592.291235.67427.57326.610323.447918.96313.139211.28037.7187QC'd by Selleck
Cytotoxic0.016682.99983Complete curve; high efficacy-7.77924.44950.914818.7882101.7872-1.10 0 0 0 0 0 0 0 0 0 01.306589.3692109.2888105.280939.259712.56078.63117.245227.937241.290725.02181.3065QC'd by BIOMOL
Cytotoxic0.0026124.131382Complete curve; high efficacy-8.57921.47810.986411.3246135.4559-1.10 0 0 0 0 0 0 0 0 0 014.9487124.278272.55539.097213.763318.160410.303510.566110.76498.90756.618214.9487QC'd by Tocris
Cytotoxic0.0209112.54382Complete curve; high efficacy-7.67921.96730.932614.5764127.1195-1.10 0 0 0 0 0 0 0 0 0 00.7959123.8363116.6866132.122462.186831.22417.327713.62456.960345.1415.10240.7959QC'd by NCGCChem
Cytotoxic0.104980.762282Complete curve; high efficacy-6.97923.990.931416.214996.9771-1.10 0 0 0 0 0 0 0 0 0 02.1195101.382375.2262112.248999.869687.632124.000528.457125.40816.87938.90662.1195QC'd by ChemAxon
Cytotoxic0.234892.655582Complete curve; high efficacy-6.62920.90.986616.7612109.4167-1.10 0 0 0 0 0 0 0 0 0 013.3983112.307799.4639110.160599.618592.250163.412843.116934.989225.203720.221113.3983QC'd by JohnsHopkins
Cytotoxic0.0264105.223682Complete curve; high efficacy-7.57922.78680.988110.1409115.3645-1.10 0 0 0 0 0 0 0 0 0 05.3828108.8197112.7123124.379475.066919.974411.747517.45588.74528.59417.9615.3828QC'd by Selleck
Cytotoxic0.93588.261382Complete curve; high efficacy-6.02921.78850.855620.4336108.6949-1.10 0 0 0 0 0 0 0 0 0 04.852785.5635121.1104117.096194.650799.9913137.032269.811848.833229.794829.96994.8527QC'd by Selleck
Cytotoxic0.0059119.868782Complete curve; high efficacy-8.22920.90.98910.4647130.3334-1.10 0 0 0 0 0 0 0 0 0 09.7544119.720688.055968.561935.492830.376516.190110.80912.106211.21728.0079.7544QC'd by Tocris
Cytotoxic0.4176152.652182Complete curve; high efficacy-6.37920.40.9686-18.9995133.6526-1.10 0 0 0 0 0 0 0 0 0 02.9146127.427102.6532123.629693.093583.859362.24155.771444.320918.43846.1372.9146QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_L363-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.011864.8887Complete curve; high efficacy-7.92923.990.906542.9911107.8711-1.10 0 0 0 0 0 0 0 0 0 175.9379117.166298.059101.666744.543237.931551.79645.54545.89855.696524.21575.9379QC'd by ChemAxon
Cytotoxic0.001086Complete curve; high efficacy-900.8727.00327.003-1.10 0 0 0 0 0 0 0 0 0 011.714116.109651.782338.477438.14932.576327.00321.712513.65628.24944.831811.714QC'd by Tocris
Cytotoxic0.014887.3385Complete curve; high efficacy-7.82922.72020.839428.2225115.5525-1.10 0 0 0 0 0 0 0 0 0 02.7164112.6565118.5558105.208650.461432.896456.123844.203245.685613.05273.96712.7164QC'd by ChemAxon
Cytotoxic0.074381.047985Complete curve; high efficacy-7.12922.40640.987736.057117.1048-1.10 0 0 0 0 0 0 0 0 0 036.612118.1815112.941121.7674108.916987.133342.59131.000532.05139.154343.592636.612QC'd by Selleck
Cytotoxic0.013295.183485Complete curve; high efficacy-7.87922.58840.978930.3117125.4951-1.10 0 0 0 0 0 0 0 0 0 022.3434119.5176131.0238109.768849.199641.232339.094429.184232.449924.950225.888622.3434QC'd by Tocris
Cytotoxic0.037296.952684Complete curve; high efficacy-7.42923.67720.943926.3959123.3485-1.10 0 0 0 0 0 0 0 0 0 020.4921101.7407120.2132147.5217112.769437.937439.317124.381225.076727.694220.417320.4921QC'd by Selleck
Cytotoxic0.1147102.026284Complete curve; high efficacy-6.94040.40.945728.8277130.8539-1.10 0 0 0 0 0 0 0 0 0 1108.0014122.9006125.5314115.924689.870995.612875.420675.658466.669245.064945.6837108.0014QC'd by Selleck
Cytotoxic0.009390.158484Complete curve; high efficacy-8.02921.71370.962524.1405114.2989-1.10 0 0 0 0 0 0 0 0 0 020.1633106.7519116.404475.80742.460431.644837.517319.116617.345730.109618.866820.1633QC'd by NCGCChem
Cytotoxic0.468669.609184Complete curve; high efficacy-6.32921.69240.827647.7156117.3247-1.10 0 0 0 0 0 0 0 0 0 195.324899.0689105.4815112.5472134.071139.294895.863678.07556.20561.315734.97695.3248QC'd by Microsource
Cytotoxic0.295785.225883Complete curve; high efficacy-6.52924.95490.905530.0023115.2281-1.10 0 0 0 0 0 0 0 0 1 045.1208102.1961108.7224107.4279107.404145.4631114.174621.348922.64833.189677.55645.1208QC'd by NCGCChem
Cytotoxic0.0118107.387883Complete curve; high efficacy-7.92924.44950.994618.1514125.5392-1.10 0 0 0 0 0 0 0 0 0 1103.6539130.2388120.1313117.134124.788321.804212.746820.289419.91221.366715.3748103.6539QC'd by Selleck
Cytotoxic0.033278.333383Complete curve; high efficacy-7.47924.44950.957520.808999.1422-1.10 0 0 0 0 0 0 0 0 0 1105.677694.56286.401118.767388.388324.521523.716318.859423.322922.567716.9857105.6776QC'd by Chemscene
Cytotoxic0.011886.29183Complete curve; high efficacy-7.92920.910.971220.4028106.6938-1.10 0 0 0 0 0 0 0 0 0 013.990798.3598100.650970.772445.884940.959433.218425.044519.165723.31217.822613.9907QC'd by Selleck
Cytotoxic0.234884.542283Complete curve; high efficacy-6.62921.10.954725.2427109.7849-1.10 0 0 0 0 0 0 0 0 0 1114.3833102.02113.1558103.8422121.074381.328372.684251.920531.812126.372328.0582114.3833QC'd by ChemieTek
Cytotoxic0.014886.1283Complete curve; high efficacy-7.82922.18760.972516.3085102.4286-1.10 0 0 0 0 0 0 0 0 0 07.9507102.926198.733390.777842.92222.299723.200730.230611.653910.657913.08247.9507QC'd by Selleck
Cytotoxic0.148277.093883Complete curve; high efficacy-6.82924.95490.955322.412899.5066-1.10 0 0 0 0 0 0 0 0 0 09.87102.096792.544998.652790.3526113.472742.025228.643431.5424.979314.77199.87QC'd by Chemscene
Cytotoxic0.417691.373683Complete curve; high efficacy-6.37921.69240.985829.7282121.1017-1.10 0 1 0 0 0 0 0 0 0 021.3801116.2452129.3034186.5441118.5918113.5565105.088162.785435.762934.74535.353721.3801QC'd by Selleck
Cytotoxic1.04987.361683Complete curve; high efficacy-5.979210.877236.1973123.5589-1.10 0 0 0 0 0 0 0 0 0 054.1491117.4289109.6638131.7472129.0154136.577793.933688.945583.642543.457225.12354.1491QC'd by SynKinase
Cytotoxic0.1482113.990583Complete curve; high efficacy-6.82921.28760.888823.8075137.7981-1.10 0 0 0 0 0 0 0 0 0 08.0453114.2505119.5624176.2421137.6679106.682559.028455.250738.182324.837127.40678.0453QC'd by Tocris
Cytotoxic1.17785.496383Complete curve; high efficacy-5.92923.62720.914939.2135124.7097-1.10 0 0 0 0 0 0 0 0 0 027.6517113.2381135.3021111.0564135.5045142.3677111.5001118.811556.830633.204257.637227.6517QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_OCIMY7-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.0148138.417292Complete curve; high efficacy-7.82920.80.985473.4473211.8645-1.10 0 0 0 0 0 0 0 0 0 076.0615206.4576176.3477160.675143.036102.215687.458676.386675.942381.513271.284576.0615QC'd by Selleck
Cytotoxic0.1865129.709492Complete curve; high efficacy-6.72922.47290.9102104.5908234.3002-1.10 0 0 0 0 0 0 0 0 0 097.9499212.7695199.584247.0735277.3731227.6905162.5507123.8591102.5004104.1059104.398997.9499QC'd by SantaCruz Bio
Cytotoxic0.525872.960991Complete curve; high efficacy-6.27922.72020.9263121.6641194.625-1.10 0 0 0 0 0 0 0 0 0 1182.846196.2276201.2704206.5478177.6678187.1047193.8819153.4274124.7553110.5225133.7805182.846QC'd by SIGMA
Cytotoxic0.0469134.726691Complete curve; high efficacy-7.32922.33320.942779.2711213.9977-1.10 0 0 0 0 0 0 0 0 0 074.524225.8348183.7696233.1661192.207130.243974.8439101.457875.21388.15864.064774.524QC'd by Selleck
Cytotoxic0.001091Complete curve; high efficacy-900.973648.780348.7803-1.10 0 0 0 0 0 0 0 0 0 047.83166.158106.533567.344835.203147.280344.656348.780346.703651.704556.888247.83QC'd by Tocris
Cytotoxic0.001090Complete curve; high efficacy-900.820746.422646.4226-1.10 0 0 0 0 0 0 0 0 0 05.4032205.1041113.398945.042360.965955.970682.491946.422618.259210.66488.46975.4032QC'd by Tocris
Cytotoxic1.481867.805689Complete curve; high efficacy-5.82924.95490.7621141.433209.2386-1.10 0 0 0 0 0 0 0 0 0 0116.0869187.3686222.298199.2101217.5801185.2508221.0682234.3031161.6854158.4572150.9575116.0869QC'd by ChemAxon
Cytotoxic0.001089Complete curve; high efficacy-900.959138.870638.8706-1.10 0 0 0 0 0 0 0 0 0 039.1109165.4745147.989392.122638.870647.652815.964314.55779.16457.80787.070839.1109QC'd by Selleck
Cytotoxic0.001089Complete curve; high efficacy-900.938841.142141.1421-1.10 0 0 0 0 0 0 0 0 0 03.8961184.0933141.73391.783118.669184.427141.142140.416126.249718.52235.72733.8961QC'd by Selleck
Cytotoxic0.001089Complete curve; high efficacy-900.988840.837940.8379-1.11 0 0 0 0 0 0 0 0 0 026.1407121.6554195.8384155.511388.106368.094737.765640.837940.099127.971631.77326.1407QC'd by Selleck
Cytotoxic0.038292.573488Complete curve; high efficacy-7.4180.40.889752.7945145.3679-1.10 0 0 0 0 0 0 0 0 0 051.9291116.2057136.3435103.092491.965479.473982.026983.101367.37361.55557.499951.9291QC'd by ChemPacific
Cytotoxic0.0743134.535488Complete curve; high efficacy-7.12921.210.930757.9113192.4467-1.10 0 0 0 0 0 0 0 0 0 049.7147175.8519207.2976185.8686162.8742143.048663.049199.107467.380557.937949.251549.7147QC'd by ChemAxon
Cytotoxic0.001088Complete curve; high efficacy-900.875833.721233.7212-1.10 0 0 0 0 0 0 0 0 0 04.1324152.461297.589368.749932.264258.815947.257833.72128.80494.81863.54334.1324QC'd by Microsource
Cytotoxic3.722185.223987Complete curve; high efficacy-5.42924.95490.891150.0271235.251-1.11 0 0 0 0 0 0 0 0 0 0154.7033204.9209231.691212.9559243.8102227.9286234.025230.2626264.0915159.589149.6383154.7033QC'd by SIGMA
Cytotoxic1.3207106.100387Complete curve; high efficacy-5.87921.82650.9417105.4088211.509-1.10 0 0 0 0 0 0 0 0 0 0114.0374223.8378192.8578196.2457228.3532212.5214209.5506192.8647146.6919120.128291.3668114.0374QC'd by XcessBio
Cytotoxic0.1482151.498787Complete curve; high efficacy-6.82920.70.9856.0265207.5252-1.10 1 0 0 0 0 0 0 0 0 051.814202.2596122.7624197.3713167.7834153.3308139.098485.59679.140368.517869.503551.814QC'd by Selleck
Cytotoxic0.093570.605687Complete curve; high efficacy-7.02924.50450.961352.9846123.5901-1.10 1 0 0 0 0 0 0 0 0 041.374115.1832175.7294133.236122.1014112.51554.255357.095263.733753.56750.781741.374QC'd by SynKinase
Cytotoxic0.001087Complete curve; high efficacy-900.957630.251130.2511-1.10 0 0 0 0 0 0 0 0 0 07.7137142.2621159.750441.789140.52422.573521.992937.056330.251115.915614.28657.7137QC'd by Selleck
Cytotoxic0.001087Complete curve; high efficacy-900.935330.652530.6525-1.10 0 0 0 0 0 0 0 0 0 010.0983153.490588.457756.636528.973143.343733.830730.652518.384511.756211.590310.0983QC'd by Selleck
Cytotoxic0.2635171.464186Complete curve; high efficacy-6.57924.95490.90355.2524226.7165-1.10 0 0 0 0 0 0 0 0 0 087.6192224.0953196.7275198.1303295.2794221.4309194.687546.556551.514833.151858.588387.6192QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-MM1R-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.0093104.652788Complete curve; high efficacy-8.02921.96730.994643.2871147.9397-1.10 0 0 0 0 0 0 0 0 0 046.9856151.2515136.3124112.156860.347441.289143.600645.536740.858441.487544.24846.9856QC'd by Cayman
Cytotoxic0.052690.729187Complete curve; high efficacy-7.27921.24750.96949.3002140.0293-1.10 0 0 0 0 0 0 0 0 0 036.2116136.8931136.6639140.7519111.565496.338258.16355.06458.665957.368148.852936.2116QC'd by Selleck
Cytotoxic0.1865111.099886Complete curve; high efficacy-6.72921.55790.959758.0636169.1634-1.10 0 0 0 0 0 0 0 0 0 030.8392165.6134164.7399166.9572172.8379153.7472111.421772.293771.432370.561564.820230.8392QC'd by Tocris
Cytotoxic0.104999.253786Complete curve; high efficacy-6.97923.1320.878851.4415150.6952-1.10 0 0 0 0 0 0 0 0 0 04.3763133.6762159.094152.6324154.4225134.385464.985170.629468.541858.555955.58134.3763QC'd by Selleck
Cytotoxic0.331794.992984Complete curve; high efficacy-6.47920.30.952137.641132.6338-1.10 0 0 0 0 0 0 0 0 0 050.4436114.4568123.9845113.833196.15292.162489.666481.881579.922468.155859.613750.4436QC'd by Tocris
Cytotoxic0.742784.904484Complete curve; high efficacy-6.12922.25260.93345.6644130.5688-1.10 0 0 0 0 0 0 0 0 0 036.4643134.3384115.1991125.3701119.0101144.1666143.817297.989150.782553.051854.389936.4643QC'd by Tocris
Cytotoxic0.833375.35484Complete curve; high efficacy-6.07923.990.961446.5835121.9376-1.10 0 0 0 0 0 0 0 0 0 033.0973124.2208119.0164110.2614120.2463126.3612130.9298108.885950.932550.258656.053633.0973QC'd by Selleck
Cytotoxic0.372288.076284Complete curve; high efficacy-6.42924.44950.970337.6549125.7311-1.10 0 0 0 0 0 0 0 0 0 044.0074106.5992127.2247130.6238138.3415127.8948120.698748.218435.913536.364134.92644.0074QC'd by Selleck
Cytotoxic0.0093130.642584Complete curve; high efficacy-8.02920.90.986724.621155.2635-1.10 0 0 0 0 0 0 0 0 0 018.1076143.3641125.709898.568566.033436.988237.469536.872131.027325.006419.273518.1076QC'd by Toronto Research
Cytotoxic0.468684.349983Complete curve; high efficacy-6.32923.06540.892737.763122.1129-1.10 0 0 0 0 0 0 0 0 0 08.9174100.9718133.1095113.0152128.6977133.2765119.584364.278453.378148.528644.758.9174QC'd by SynKinase
Cytotoxic0.331788.677483Complete curve; high efficacy-6.47921.62590.990934.1483122.8257-1.10 0 0 0 0 0 0 0 0 0 032.8455112.8257122.9968126.477124.3559121.535296.460460.397143.403334.092232.873332.8455QC'd by JohnsHopkins
Cytotoxic0.2957104.439583Complete curve; high efficacy-6.52920.60.963633.4657137.9052-1.10 0 0 0 0 0 0 0 0 0 030.41139.5422127.9789115.7906133.779110.19387.959673.595558.104955.361347.914130.41QC'd by JohnsHopkins
Cytotoxic2.348586.675883Complete curve; high efficacy-5.62924.0950.968453.6121140.2879-1.10 0 0 0 0 0 0 0 0 0 051.2528135.5146146.9511127.3268148.5202130.0159143.2286148.4195122.370157.612755.742751.2528QC'd by LINCS
Cytotoxic0.589978.481583Complete curve; high efficacy-6.229210.96239.6422118.1236-1.10 0 0 0 0 0 0 0 0 0 036.8849113.0988105.5924123.1519126.3882114.847893.448478.396461.99652.62141.616136.8849QC'd by NCGCChem
Cytotoxic1.662685.967283Complete curve; high efficacy-5.77922.47290.929540.7279126.6952-1.10 0 0 0 0 0 0 0 0 0 028.4756118.8121112.7597122.0662124.4452131.3159149.7541122.838280.294449.812550.994128.4756QC'd by Microsource
Cytotoxic0.074390.741383Complete curve; high efficacy-7.12921.96730.946425.6492116.3905-1.10 0 0 0 0 0 0 0 0 0 05.9198106.5785111.2723128.5693109.673979.414437.115833.672241.61829.688719.14745.9198QC'd by Selleck
Cytotoxic0.4176196.850483Complete curve; high efficacy-6.37920.30.9606-31.7676165.0828-1.10 0 0 0 0 0 0 0 0 0 02.8348135.921148.6439123.1507111.473178.544671.308564.760262.7228.685414.04622.8348QC'd by Microsource
Cytotoxic0.525895.995583Complete curve; high efficacy-6.27920.40.975335.9633131.9588-1.10 0 0 0 0 0 0 0 0 0 050.6988124.3759129.0401111.2096110.666498.319199.274582.50577.957559.853253.136550.6988QC'd by Microsource
Cytotoxic0.1865153.297482Complete curve; high efficacy-6.72920.40.9838-19.1976134.0998-1.10 0 0 0 0 0 0 0 0 0 01.5971128.3939102.50195.957690.349376.112759.654643.641425.05494.92791.71.5971QC'd by NCGCChem
Cytotoxic0.4686112.636982Complete curve; high efficacy-6.32920.70.96616.772129.4089-1.10 0 0 0 0 0 0 0 0 0 013.877117.2722122.3984135.2437130.0817105.741580.360967.039351.753440.54130.169413.877QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-mm1s-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.013278.888888Complete curve; high efficacy-7.87923.51170.995147.2347126.1235-1.10 0 0 0 0 0 0 0 0 0 042.2827127.6613122.708120.202461.112651.288545.516147.740746.357847.533948.054342.2827QC'd by SigmaAldrich
Cytotoxic0.018794.499187Complete curve; high efficacy-7.72921.96730.992343.1973137.6963-1.10 0 0 0 0 0 0 0 0 0 047.5181141.319129.8171127.504186.807649.094247.049942.27740.938537.815144.862147.5181QC'd by ACC
Cytotoxic0.525873.986887Complete curve; high efficacy-6.27921.53860.960875.2185149.2053-1.10 0 0 0 0 0 0 0 0 0 066.1566142.7053154.8249147.903146.0134146.4254144.006104.273988.096990.959471.649566.1566QC'd by JohnsHopkins
Cytotoxic0.0059140.454587Complete curve; high efficacy-8.22921.41630.968736.1127176.5672-1.10 0 0 0 0 0 0 0 0 0 010.8624168.6765147.515496.349154.200241.544537.572842.209341.742240.483343.494610.8624QC'd by Cayman
Cytotoxic0.013279.744487Complete curve; high efficacy-7.87920.60.898641.6151121.3595-1.10 0 0 0 0 0 0 0 0 0 026.1462113.0499103.137682.203181.485258.693853.314553.669254.537937.118656.47926.1462QC'd by SigmaAldrich
Cytotoxic0.166378.942786Complete curve; high efficacy-6.77923.92950.945949.4968128.4395-1.10 0 0 0 0 0 0 0 0 0 039.1638119.9619118.7114121.8873145.134135.660277.501949.371642.704855.488760.915639.1638QC'd by SynKinase
Cytotoxic0.117799.522986Complete curve; high efficacy-6.92920.50.978453.5004153.0233-1.10 0 0 0 0 0 0 0 0 0 054.2364146.2425146.4285127.5196118.6607112.3725102.003786.351770.597462.725470.168354.2364QC'd by Selleck
Cytotoxic0.234879.922286Complete curve; high efficacy-6.62921.46410.979158.9416138.8638-1.10 0 0 0 0 0 0 0 0 0 062.4132143.4278135.9313129.1028144.3799129.2524105.203973.502570.461953.739757.639662.4132QC'd by BIOMOL
Cytotoxic0.0187133.261986Complete curve; high efficacy-7.72920.60.944135.7906169.0525-1.10 0 0 0 0 0 0 0 0 0 027.5582156.1894139.4018135.437491.108661.224166.094967.717153.596142.584230.965227.5582QC'd by Toronto Research
Cytotoxic0.029679.81285Complete curve; high efficacy-7.52923.1320.836730.4945110.3065-1.10 0 0 0 0 0 0 0 0 0 0-0.421991.4427118.502121.280287.417839.0630.378326.00428.811631.88664.9696-0.4219QC'd by ChemAxon
Cytotoxic0.468672.558485Complete curve; high efficacy-6.32921.47810.89858.4082130.9666-1.10 0 0 0 0 0 0 0 0 0 036.5241121.5091138.67123.1995141.6082124.8321119.084385.203570.543862.760678.203936.5241QC'd by SIGMA
Cytotoxic0.574989.317185Complete curve; high efficacy-6.24043.51170.938153.4216142.7387-1.10 0 0 0 0 0 0 0 0 0 042.1397122.2594133.5752138.8262155.9137150.9759155.3277133.833270.150756.140464.45942.1397QC'd by Selleck
Cytotoxic0.104990.112685Complete curve; high efficacy-6.97921.10.9642.4601132.5727-1.10 0 0 0 0 0 0 0 0 0 048.0597134.7202138.2028122.4795111.2704105.46677.884945.23345.497230.823755.272548.0597QC'd by Tocris
Cytotoxic0.041880.357885Complete curve; high efficacy-7.37920.60.851133.6315113.9892-1.10 0 0 0 0 0 0 0 0 0 011.0841101.2736106.771596.716682.13570.480940.105551.505451.453654.137541.943611.0841QC'd by Microsource
Cytotoxic0.661994.77385Complete curve; high efficacy-6.17921.47810.980353.7716148.5446-1.10 0 0 0 0 0 0 0 0 0 055.0629148.0214138.5482154.1536143.4321157.4598136.588499.863477.243358.434452.819555.0629QC'd by Selleck
Cytotoxic0.2093116.503485Complete curve; high efficacy-6.67921.3310.904546.5044163.0078-1.10 0 0 0 0 0 0 0 0 0 013.0869143.6239161.4686168.1578159.9801164.488797.670664.784668.491371.476350.62513.0869QC'd by Selleck
Cytotoxic0.295796.448284Complete curve; high efficacy-6.52921.82650.979336.1131132.5613-1.10 0 0 0 0 0 0 0 0 0 027.7595137.6757133.1247125.0579141.4133118.8792106.669652.975840.619540.756544.348527.7595QC'd by BIOMOL
Cytotoxic0.372296.5784Complete curve; high efficacy-6.42921.47870.980840.3311136.901-1.10 0 0 0 0 0 0 0 0 0 041.4841141.6948138.6029123.988145.2114122.9084114.816475.052646.365545.832838.682941.4841QC'd by BIOMOL
Cytotoxic0.013299.542284Complete curve; high efficacy-7.87920.50.859825.2368124.779-1.10 0 0 0 0 0 0 0 0 0 033.6254113.8403106.930467.885457.737956.717356.006446.273443.48929.15714.453233.6254QC'd by NCGCChem
Cytotoxic2.093175.060284Complete curve; high efficacy-5.67924.95490.948360.3489135.4091-1.10 0 0 0 0 0 0 0 0 0 060.7384119.1757138.3496139.0789136.1425149.2097137.4143127.2154116.932554.542266.866760.7384QC'd by ChemAxon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-KMS-28PE-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Inconclusive2.093152.377810Complete curve; partial efficacy; poor fit-5.67921.210.8868207.717155.33921.40 0 0 0 1 0 0 0 0 0 1147.1164.4833155.0085150.5868148.3401116.6514156.9711173.7174168.6881199.2135202.8962147.1QC'd by Microsource
Inconclusive0.005712.519610Complete curve; partial efficacy; poor fit-8.24044.95490.312131.5823119.06271.40 0 0 0 0 0 0 0 0 0 1127.1473120.0823122.1295115.8993137.6706122.1335127.163123.7971150.7316133.1825125.6113127.1473QC'd by SIGMA
Inconclusive0.00192110Complete curve; partial efficacy; poor fit-8.72921.10.8356134.2114113.21141.40 0 0 0 0 0 0 0 0 0 1119.1302117.2114127.4759130.4637129.9536131.9164134.6866133.4534131.6405137.8111137.2931119.1302QC'd by Pharmeks
Inconclusive0.066221.510Complete curve; partial efficacy; poor fit-7.17921.96730.9617136.1907114.69071.40 0 0 0 0 0 0 0 0 0 0137.9456114.6907115.3457114.9342114.9118125.4369132.2852136.9063134.4597139.5384132.1379137.9456QC'd by Sequoia
Inconclusive0.148221.099810Complete curve; partial efficacy; poor fit-6.82920.80.8442149.6919128.59211.40 0 0 0 0 0 0 0 0 0 0151.9116131.6919128.2754129.76129.967133.7039147.8377137.7359147.2819148.9579147.0679151.9116QC'd by Tocris
Inconclusive0.083330.510Complete curve; partial efficacy; poor fit-7.07920.30.9065152.817122.3171.40 0 0 0 0 0 0 0 0 0 0149.8479126.317131.9239133.2597133.1414138.2988138.8257144.3744142.6826141.1244150.4849149.8479QC'd by APAC
Inconclusive0.0032310Complete curve; partial efficacy; poor fit-8.52920.70.9042116.673193.67311.40 0 0 0 0 0 0 0 0 0 0115.023597.6731106.1567108.9656113.5207111.3295114.3155115.674116.5526117.8964119.9437115.0235QC'd by SigmaAldrich
Inconclusive0.001925.510Complete curve; partial efficacy-8.72921.55790.7725134.9997109.49971.20 0 0 0 0 0 0 0 0 0 0138.6831113.4997125.8748129.6566135.9028133.275139.8144131.171127.5454138.1274135.3784138.6831QC'd by SigmaAldrich
Inactive0-5.02920.80.4643103.7426121.954440 0 0 0 0 0 0 0 0 0 0106.6946111.4544125.2432128.5053127.1929113.4715124.3917121.815114.296116.6521111.8738106.6946QC'd by BIOMOL
Inactive04125.6815122.8795130.2888125.1136125.6652130.3074128.7078129.9384126.7494127.6785129.7132125.6815QC'd by BIOMOL
Inactive04136.2326163.4273142.6615146.3348166.6634150.6103158.3404165.0578162.7658150.3198139.9664136.2326QC'd by BIOMOL
Inactive0-7.37920.80.6066126.3684141.901940 0 0 0 0 0 0 0 0 0 0126.5818144.4019133.558143.8479137.0521128.3337135.1801122.2906134.5644123.4653125.8628126.5818QC'd by BIOMOL
Inactive0-4.92924.95490.7372120.4574134.013840 0 0 0 0 0 0 0 0 0 0120.7168134.5138134.0383138.0285138.2397129.2732130.6596135.9635130.2877134.4747123.0085120.7168QC'd by BIOMOL
Inactive0-6.87923.1320.4017111.9315106.526540 0 0 0 0 0 0 0 0 0 1105.5505105.9315109.5176101.4274110.4744106.5334110.4821115.977107.3312113.281111.1989105.5505QC'd by BIOMOL
Inactive0-4.67924.50450.6481132.5399143.83940 0 0 0 0 0 0 0 0 0 0132.7564143.839141.5609139.3268147.1235144.923140.6337146.4103146.2306145.3224141.4193132.7564QC'd by BIOMOL
Inactive0-4.57920.90.6882159.3525129.352540 0 0 0 0 0 0 0 0 0 0151.1525125.3525127.8444130.5681128.6677140.8596130.7582127.8002131.1106130.9549139.8805151.1525QC'd by BIOMOL
Inactive0-6.97920.40.9481115.525797.048340 0 0 0 0 0 0 0 0 0 0114.535699.525798.7112102.3247103.7206107.7162106.0966108.4061110.7209110.6769114.5412114.5356QC'd by BIOMOL
Inactive0-5.17922.40640.5201113.1718140.123540 0 0 0 0 0 0 0 0 0 0115.0077144.1235142.7954132.4372151.4407117.6804133.3272147.8257140.0962131.6466114.5804115.0077QC'd by BIOMOL
Inactive04129.9994131.8514126.6454132.768130.4791123.0823132.8921130.718134.7376125.1039126.4003129.9994QC'd by BIOMOL
Inactive0-5.97923.51170.87899.8725117.809540 0 0 0 0 0 0 0 0 0 0106.7355120.8095114.2948118.894116.6347119.8485116.4782116.0413102.243498.24195.0287106.7355QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-LP_1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.010587.390386Complete curve; high efficacy-7.97921.55790.989332.5525119.9428-1.10 0 0 0 0 0 0 0 0 0 032.5973120.122108.670192.358749.68844.854932.131433.603134.763228.3332.048332.5973QC'd by Tocris
Cytotoxic0.008376.084786Complete curve; high efficacy-8.07922.40640.978834.0695110.1542-1.10 0 0 0 0 0 0 0 0 0 024.173108.041107.758381.913639.516542.556837.70132.500733.657937.059831.016624.173QC'd by Toronto Research
Cytotoxic0.018777.542886Complete curve; high efficacy-7.72921.78850.962734.3529111.8957-1.10 0 0 0 0 0 0 0 0 0 033.0008112.3533115.065889.919978.411730.490234.730734.354633.092838.520140.803433.0008QC'd by Selleck
Cytotoxic0.05988.700585Complete curve; high efficacy-7.22920.60.969436.3948125.0953-1.10 0 0 0 0 0 0 0 0 0 028.5989117.1885119.5312102.469690.645885.862360.636451.829952.266249.734541.128528.5989QC'd by Selleck
Cytotoxic0.033277.128185Complete curve; high efficacy-7.47920.70.965531.2029108.331-1.10 0 0 0 0 0 0 0 0 0 022.5571101.2018101.265588.845670.184569.842243.682140.23739.306637.25836.404722.5571QC'd by Selleck
Cytotoxic0.018779.858785Complete curve; high efficacy-7.72923.51170.958432.0611111.9199-1.10 0 0 0 0 0 0 0 0 0 013.2093112.4294107.1384115.125260.413141.924537.316331.47637.27735.928730.843213.2093QC'd by Cayman
Cytotoxic0.093586.449185Complete curve; high efficacy-7.02921.10.944937.248123.6972-1.10 0 0 0 0 0 0 0 0 0 026.2605129.9165117.2503108.9438120.53891.515551.119756.159151.860742.057332.899826.2605QC'd by Tocris
Cytotoxic0.020993.129385Complete curve; high efficacy-7.67921.46410.961833.1188126.2481-1.10 0 0 0 0 0 0 0 0 0 022.4794117.474125.7046121.844767.966156.055641.326142.215733.927132.351729.697222.4794QC'd by Selleck
Cytotoxic0.0332100.48585Complete curve; high efficacy-7.479210.970731.2298131.7149-1.10 0 0 0 0 0 0 0 0 0 025.5067135.567116.3384110.9262105.252653.915347.874942.057435.306632.7930.969525.5067QC'd by SIGMA
Cytotoxic0.029693.442184Complete curve; high efficacy-7.52923.92950.974823.6719117.114-1.10 0 0 0 0 0 0 0 0 0 025.7428100130.2442120.83397.558327.822521.54819.831323.18926.683424.643725.7428QC'd by SigmaAldrich
Cytotoxic0.372276.55184Complete curve; high efficacy-6.42921.210.930841.5458118.0968-1.10 0 0 0 0 0 0 0 0 0 026.8735126.0105102.8329112.503124.3981120.178987.830470.201454.107949.917250.88526.8735QC'd by ChemieTek
Cytotoxic0.132181.241484Complete curve; high efficacy-6.87924.95490.942234.404115.6454-1.10 0 0 0 0 0 0 0 0 0 026.3475111.8181103.4247109.6276115.8533135.698144.775439.68148.652328.651829.112426.3475QC'd by Microsource
Cytotoxic0.148282.701584Complete curve; high efficacy-6.82923.92950.980732.7831115.4845-1.10 0 0 0 0 0 0 0 0 0 029.9601112.1327117.5155121.9023104.2805119.069555.455342.556433.026630.915628.938629.9601QC'd by Selleck
Cytotoxic0.05976.700284Complete curve; high efficacy-7.22921.50950.976329.9655106.6658-1.10 0 0 0 0 0 0 0 0 0 021.9818106.9151109.4753101.075790.329271.880834.561430.807840.756634.092828.492121.9818QC'd by SantaCruz Bio
Cytotoxic0.020988.802383Complete curve; high efficacy-7.67923.51170.951216.2799105.0822-1.10 0 0 0 0 0 0 0 0 0 03.7081100.414107.4471102.660964.97134.98339.840114.997917.73926.496734.02243.7081QC'd by SIGMA
Cytotoxic0.041893.574583Complete curve; high efficacy-7.37922.18760.998417.8156111.39-1.10 0 0 0 0 0 0 0 0 0 017.4361109.284114.2073106.670495.671445.860321.91818.883416.506916.328316.984617.4361QC'd by ACC
Cytotoxic0.083378.232883Complete curve; high efficacy-7.07920.80.905521.999100.2318-1.10 0 0 0 0 0 0 0 0 0 02.109590.1163103.264689.018286.322667.714235.347539.808535.914336.921628.83652.1095QC'd by ChemAxon
Cytotoxic0.074390.137383Complete curve; high efficacy-7.12920.60.939423.0787113.2161-1.10 0 0 0 0 0 0 0 0 0 014.6398104.4157102.1008106.636185.983463.333350.656440.15953.402331.917625.558714.6398QC'd by Axon Medchem
Cytotoxic0.041884.768783Complete curve; high efficacy-7.37921.22210.965421.7645106.5332-1.10 0 0 0 0 0 0 0 0 0 018.8147105.573699.2727109.218868.570462.902925.88328.211225.408922.860621.049818.8147QC'd by Selleck
Cytotoxic0.0469101.067483Complete curve; high efficacy-7.32920.90.956722.9637124.0311-1.10 0 0 0 0 0 0 0 0 0 07.6524111.1073130.7357106.619390.519265.038238.879739.549834.132432.242524.93497.6524QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Mycobacterium tuberculosis
External ID: CHEMBL3796292
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg Med Chem Lett
Year: 2016
Volume: 26
Issue: 9
First Page: 2188
Last Page: 2193
DOI: 10.1016/j.bmcl.2016.03.066

Target ChEMBL ID: CHEMBL360
ChEMBL Target Name: Mycobacterium tuberculosis
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.1IC50=100nM
0.2IC90=200nM
0.3MIC=300nM
20.8IC50=20800nM
33.1IC90=33100nM
50MIC=50000nM
1.2IC50=1200nM
1.8IC90=1800nM
6.2MIC=6200nM
5.8IC50=5800nM
11.5IC90=11500nM
12.5MIC=12500nM
0.102IC50=102nM
0.141IC90=141nM
0.2MIC=200nM
0.02IC50=20nM
0.03IC90=30nM
0.04MIC=40nM
5.4IC50=5400nM
10.7IC90=10700nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-MOLP-8-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.2348112.884984Complete curve; high efficacy-6.62920.40.939237.0886149.9734-1.11 0 0 0 0 0 0 0 0 0 047.4866100.2991140.8419123.7999110.5725117.564587.825378.249885.531267.105248.08847.4866QC'd by SantaCruz Bio
Cytotoxic0.0332135.867784Complete curve; high efficacy-7.47920.40.868624.8504160.7181-1.10 0 0 0 0 0 0 0 0 0 09.5856132.6885149.7338116.748673.778973.989769.730568.018654.415855.950840.44799.5856QC'd by SIGMA
Cytotoxic2.0931100.118383Complete curve; high efficacy-5.67920.40.953450.966151.0844-1.10 0 0 0 0 0 0 0 0 0 067.4421149.8224143.8978144.1774136.6925121.0787121.338115.4935112.696598.792974.828167.4421QC'd by Tocris
Cytotoxic0.0132104.008283Complete curve; high efficacy-7.87921.92820.988715.4484119.4565-1.10 0 0 0 0 0 0 0 0 0 04.6572119.4565113.395898.070346.344719.738622.763617.901420.621915.88212.51264.6572QC'd by Selleck
Cytotoxic0.0235123.025483Complete curve; high efficacy-7.62920.40.833719.8641142.8896-1.10 0 0 0 0 0 0 0 0 0 012.2641131.0145115.543690.295153.905271.215162.338757.160461.969514.810235.382712.2641QC'd by Cayman
Cytotoxic0.209385.298783Complete curve; high efficacy-6.67920.70.933425.0186110.3173-1.10 0 0 0 0 0 0 0 0 0 027.0991109.8173117.737596.065379.189496.830975.536451.699233.826328.186136.413327.0991QC'd by NCGCChem
Cytotoxic3.317381.307483Complete curve; high efficacy-5.47922.33320.931557.6371138.9446-1.10 0 0 0 1 0 0 0 0 0 049.2543138.4338143.9848151.4142126.008995.5126125.5596148.3456124.31378.15369.765749.2543QC'd by Selleck
Cytotoxic0.005936.966482Complete curve; partial efficacy-8.22922.33320.9077119.6572156.6236-1.20 0 0 0 0 0 0 0 0 0 0121.5044156.5384152.389136.5428116.1001121.0618114.6459112.3913119.9242122.9008128.5083121.5044QC'd by Tocris
Cytotoxic0.0235114.209482Complete curve; high efficacy-7.62920.50.976314.7696128.979-1.10 0 0 0 0 0 0 0 0 0 010.4187119.189695.722479.624580.242657.691343.007536.236630.095223.109920.65110.4187QC'd by FLUKA
Cytotoxic3.722180.870382Complete curve; high efficacy-5.42924.95490.903234.983115.8532-1.10 0 0 0 0 0 0 0 0 0 031.7555109.588598.898113.8737107.8306136.1674134.0604103.0938120.4749.927837.402931.7555QC'd by Selleck
Cytotoxic0.093590.511982Complete curve; high efficacy-7.02922.40640.907611.9163102.4282-1.10 0 0 0 0 0 0 0 0 0 012.606679.81796.8282103.1563135.242367.22833.455113.67799.624510.775711.22312.6066QC'd by Selleck
Cytotoxic0.166394.761582Complete curve; high efficacy-6.77922.25260.98616.386111.1475-1.10 0 0 0 0 0 0 0 0 0 013.149108.3556124.8245103.3906106.2074102.246958.785121.215318.077319.677216.032513.149QC'd by Selleck
Cytotoxic0.5258104.154382Complete curve; high efficacy-6.279210.941418.3838122.5381-1.10 0 0 0 0 0 0 0 0 0 011.0314104.3828126.1461116.2417132.0669128.168183.354461.552952.656732.958721.753411.0314QC'd by JohnsHopkins
Cytotoxic0.1321103.787382Complete curve; high efficacy-6.87920.90.96614.4792118.2664-1.10 0 0 0 0 0 0 0 0 0 017.9536125.3305107.6763112.1488100.702673.069975.951528.288418.604519.064616.652717.9536QC'd by Axon Medchem
Cytotoxic0.0132114.512182Complete curve; high efficacy-7.87922.04790.990314.6838129.1959-1.10 0 0 0 0 0 0 0 0 0 013.3585136.7296116.4775107.708242.698923.621911.168115.726818.095413.321414.334613.3585QC'd by ChemieTek
Cytotoxic0.1321156.013482Complete curve; high efficacy-6.87920.40.9789-13.9595142.0539-1.10 0 0 0 0 0 0 0 0 0 02.982129.411119.3857103.9503100.891163.90856.490249.420432.44885.10223.55372.982QC'd by Selleck
Cytotoxic3.722184.036682Complete curve; high efficacy-5.42921.98870.889233.1062117.1428-1.10 0 0 0 0 0 0 0 0 0 022.583104.9664128.4651118.0164124.042993.0546124.0918125.7379103.197156.428452.504522.583QC'd by XcessBio
Cytotoxic1.320784.378182Complete curve; high efficacy-5.87924.44950.910828.6573113.0354-1.10 0 0 0 0 0 0 0 0 0 050.695598.1375111.271125.1555106.5195116.7283107.7109122.303149.824127.93655.97250.6955QC'd by Microsource
Cytotoxic0.525893.379882Complete curve; high efficacy-6.27922.33320.98319.1033112.4831-1.10 0 0 0 0 0 0 0 0 0 016.8591105.468124.7832114.5473109.601102.2654109.906561.363223.850621.146220.522416.8591QC'd by Selleck
Cytotoxic0.052698.055282Complete curve; high efficacy-7.27921.50950.986815.7184113.7736-1.10 0 0 0 0 0 0 0 0 0 012.9644114.8405118.277999.487995.383561.412321.163723.874615.920820.047211.588312.9644QC'd by Axon Medchem
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Mycobacterium tuberculosis
External ID: CHEMBL3123760
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2014
Volume: 74
First Page: 664
Last Page: 670
DOI: 10.1016/j.ejmech.2013.09.061

Target ChEMBL ID: CHEMBL360
ChEMBL Target Name: Mycobacterium tuberculosis
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=51%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-MM-M1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.010576.742198Complete curve; high efficacy-7.97920.40.8143106.1488182.891-1.10 0 0 0 0 0 0 0 0 0 097.0213175.2098149.2496135.4049151.407123.166130.2765116.1855114.3842112.5027122.711897.0213QC'd by SigmaAldrich
Cytotoxic0.020959.606490Complete curve; high efficacy-7.67922.33320.874365.0446124.6509-1.10 0 0 0 0 0 0 0 0 0 042.5491114.2054125.0887133.638390.399669.076975.433362.892474.984266.982668.241342.5491QC'd by Selleck
Cytotoxic0.018799.387289Complete curve; high efficacy-7.72920.70.980954.5973153.9845-1.10 0 0 0 0 0 0 0 0 0 052144.7606143.678116.218996.581992.313370.116662.478959.112861.584152.567552QC'd by SynKinase
Cytotoxic0.417668.959788Complete curve; high efficacy-6.37923.51170.895189.8298158.7896-1.11 0 0 0 0 0 0 0 0 0 095.9522121.7497145.5234145.5172164.4127183.3401150.4309108.335677.511895.882489.823695.9522QC'd by Axon Medchem
Cytotoxic0.589969.181988Complete curve; high efficacy-6.22923.990.762995.3406164.5224-1.10 0 0 0 0 0 0 0 0 0 0109.573149.3937173.4718129.8513191.2497150.3213190.3378133.864783.187296.413691.5262109.573QC'd by Selleck
Cytotoxic0.0743107.054887Complete curve; high efficacy-7.12920.80.984554.8206161.8754-1.10 0 0 0 0 0 0 0 0 0 057.9387151.8563163.9611143.7973136.7288112.919683.16276.873368.177453.226952.637857.9387QC'd by Selleck
Cytotoxic0.148283.542787Complete curve; high efficacy-6.82924.44950.95860.4745144.0173-1.10 0 0 0 0 0 0 0 0 0 069.2734130.5346130.6652147.3751155.1668153.941881.695563.29659.260855.616355.513469.2734QC'd by Selleck
Cytotoxic1.177117.97687Complete curve; high efficacy-5.92920.30.8809103.6252221.6012-1.10 0 0 0 0 0 0 0 0 0 0124.3584204.1012213.7323210.6584195.2614187.4914165.4267159.6533180.5857156.7486132.0473124.3584QC'd by Microsource
Cytotoxic0.005986.11287Complete curve; high efficacy-8.22923.92950.940835.788121.9-1.10 0 0 0 0 0 0 0 0 0 016.9728119.2292123.80460.906149.612339.010736.652141.355244.341829.622331.979616.9728QC'd by Selleck
Cytotoxic0.661977.798687Complete curve; high efficacy-6.17921.46410.905587.7533165.5518-1.11 0 0 0 0 0 0 0 0 0 081.2811136.4201144.0668155.7612179.4399178.5787159.509126.3915103.3855100.192987.184981.2811QC'd by Selleck
Cytotoxic0.132189.890486Complete curve; high efficacy-6.87920.80.95149.0129138.9033-1.10 0 0 0 0 0 0 0 0 0 040.8231126.0203148.1813124.8099131.8805103.371579.016473.44667.02155.440553.384540.8231QC'd by Toronto Research
Cytotoxic0.4176102.258786Complete curve; high efficacy-6.37920.90.955864.4239166.6826-1.10 0 0 0 0 0 0 0 0 0 062.0508169.9186163.4857169.1241146.548155.8497143.523295.509585.826689.782263.021662.0508QC'd by JohnsHopkins
Cytotoxic1.481876.048286Complete curve; high efficacy-5.82921.64360.961186.8287162.8769-1.11 0 0 0 0 0 0 0 0 0 082.8262126.6031167.7674148.1546170.4052160.7596163.2256153.9322115.8888102.739187.384382.8262QC'd by Microsource
Cytotoxic0.93570.299185Complete curve; high efficacy-6.02921.10.944964.9721135.2712-1.10 0 0 0 0 0 0 0 0 0 054.1264136.8416133.7919124.0367139.8306136.3935126.542109.431383.56279.460279.257954.1264QC'd by Selleck
Cytotoxic0.1049113.233785Complete curve; high efficacy-6.97921.10.946739.4295152.6631-1.10 0 0 0 0 0 0 0 0 0 032.5405140.1803150.363153.1014157.369294.872271.375973.052248.593136.378239.149432.5405QC'd by Selleck
Cytotoxic0.0166145.913585Complete curve; high efficacy-7.77920.70.982429.6583175.5718-1.10 0 0 0 0 0 0 0 0 0 034.6378162.9357140.528136.147383.994477.337854.505136.927832.978933.61429.924334.6378QC'd by Selleck
Cytotoxic0.742787.807885Complete curve; high efficacy-6.12921.82650.8961.3799149.1877-1.10 0 0 0 0 0 0 0 0 0 043.6517125.4482151.4934151.5693138.7177162.0934165.3929104.484285.588670.237469.183243.6517QC'd by SynKinase
Cytotoxic0.002672.145785Complete curve; high efficacy-8.57921.22210.943724.741896.8875-1.10 0 0 0 0 0 0 0 0 0 016.212489.740360.566940.694133.868835.347627.530728.413321.997521.291722.494316.2124QC'd by Selleck
Cytotoxic0.935100.642185Complete curve; high efficacy-6.02920.70.92361.7833162.4254-1.10 0 0 0 0 0 0 0 0 0 057.3523168.1282144.1115151.7026171.4086158.4019133.5552112.5955103.328285.466988.368357.3523QC'd by Selleck
Cytotoxic2.635188.832385Complete curve; high efficacy-5.57920.80.900992.8317181.664-1.10 0 0 0 0 0 0 0 0 0 098.7032172.664175.775187.4451189.4966178.714170.8024149.3555161.8016111.5356120.77798.7032QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Mycobacterium tuberculosis
External ID: CHEMBL3123761
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2014
Volume: 74
First Page: 664
Last Page: 670
DOI: 10.1016/j.ejmech.2013.09.061

Target ChEMBL ID: CHEMBL360
ChEMBL Target Name: Mycobacterium tuberculosis
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=26.7%
Inhibition=93.9%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-OCI_MY1-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.093583.133787Complete curve; high efficacy-7.02920.60.973252.9139136.0477-1.10 0 0 0 0 0 0 0 0 0 054.7559135.1374118.648125.1116118.336796.366979.597475.149571.390359.692254.239654.7559QC'd by Selleck
Cytotoxic0.0332111.725186Complete curve; high efficacy-7.47920.30.926242.1257153.8508-1.10 0 0 0 0 0 0 0 0 0 051.7825144.6362112.8549103.828595.219288.923187.26580.966170.718165.599553.464751.7825QC'd by Cayman
Cytotoxic0.041882.751485Complete curve; high efficacy-7.37920.50.975933.8657116.617-1.10 0 0 0 0 0 0 0 0 0 028.5726108.62298.686993.798783.828667.416856.438356.969748.110946.342837.744328.5726QC'd by SynKinase
Cytotoxic0.029692.090785Complete curve; high efficacy-7.52920.50.938335.476127.5667-1.10 0 0 0 0 0 0 0 0 0 029.5556114.1336120.894588.726181.575576.202554.682455.648457.304545.91137.137429.5556QC'd by SynKinase
Cytotoxic0.186570.386984Complete curve; high efficacy-6.72922.72020.976138.0815108.4684-1.10 0 0 0 0 0 0 0 0 0 047.1917108.8739108.2531101.5408112.4163108.138570.335743.665234.539228.36141.664847.1917QC'd by JohnsHopkins
Cytotoxic0.417671.667384Complete curve; high efficacy-6.37922.40640.947943.4067115.074-1.10 0 0 0 0 0 0 0 0 0 033.3089105.574126.981118.3238117.612103.7019109.683463.443852.586453.630639.122233.3089QC'd by Selleck
Cytotoxic0.1049108.159184Complete curve; high efficacy-6.97920.30.95531.5875139.7466-1.10 0 0 0 0 0 0 0 0 0 043.3364131.0144114.5692101.756397.195681.028979.285179.03469.839955.06552.703143.3364QC'd by SynKinase
Cytotoxic0.0166112.88483Complete curve; high efficacy-7.77922.72020.988916.1533129.0373-1.10 0 0 0 0 0 0 0 0 0 013.2676116.3272134.3166126.014155.794523.838515.933916.952314.530314.265815.832113.2676QC'd by SIGMA
Cytotoxic0.468694.725883Complete curve; high efficacy-6.32920.60.955729.0284123.7542-1.10 0 0 0 0 0 0 0 0 0 035.6827133.5399103.9822117.9539112.0859105.55983.299274.084264.511341.029741.637235.6827QC'd by Selleck
Cytotoxic0.2635100.875583Complete curve; high efficacy-6.57920.90.896925.7615126.637-1.10 0 0 0 0 0 0 0 0 0 04.542104.9981131.3946122.3505135.6872112.0566.048557.839653.797641.533237.99754.542QC'd by ChemAxon
Cytotoxic0.0469103.265883Complete curve; high efficacy-7.32921.47870.994524.4756127.7413-1.10 0 0 0 0 0 0 0 0 0 022.0142133.8948120.7681119.4508105.615665.752534.739831.818124.476924.170924.920822.0142QC'd by Selleck
Cytotoxic0.468692.471283Complete curve; high efficacy-6.32922.33320.97228.9592121.4304-1.10 0 0 0 0 0 0 0 0 0 029.8907112.9759141.5986120.5517113.8929115.8225112.497662.870633.523828.959228.871129.8907QC'd by Selleck
Cytotoxic0.234889.204483Complete curve; high efficacy-6.62921.46410.977529.1453118.3497-1.10 0 0 0 0 0 0 0 0 0 030.577122.3185120.0124103.9641116.9025116.682575.578553.39729.776427.630331.59430.577QC'd by Selleck
Cytotoxic2.635188.363983Complete curve; high efficacy-5.579210.833353.4354141.7993-1.10 0 0 0 0 0 0 0 0 0 069.1826150.707126.8073140.1173122.6532128.5218127.1755136.3873123.344463.498261.630569.1826QC'd by Chemscene
Cytotoxic1.04994.696982Complete curve; high efficacy-5.97921.92820.986426.5166121.2135-1.10 0 0 0 0 0 0 0 0 0 022.4036111.8163115.5011118.7274126.8177125.7155124.411199.239253.489634.159726.65422.4036QC'd by BIOMOL
Cytotoxic0.132181.439182Complete curve; high efficacy-6.879210.970513.202594.6416-1.10 0 0 0 0 0 0 0 0 0 06.269984.6416100.214488.005489.829466.870145.105225.58927.265521.16810.12696.2699QC'd by Selleck
Cytotoxic0.083392.852382Complete curve; high efficacy-7.07920.40.970612.2421105.0944-1.10 0 0 0 0 0 0 0 0 0 015.231897.301484.070587.11564.466159.841648.860238.500140.277931.426921.966115.2318QC'd by Selleck
Cytotoxic0.023580.806982Complete curve; high efficacy-7.62920.60.988914.690995.4978-1.10 0 0 0 0 0 0 0 0 0 011.797688.131284.02266.582754.926541.216133.27229.074823.708316.203515.847511.7976QC'd by Tocris
Cytotoxic0.001259.123982Complete curve; partial efficacy-8.92924.95490.858799.4449158.5687-1.20 0 0 0 0 0 0 0 0 0 0103.2631152.614894.492295.000194.342694.4109100.4664111.3588107.5709103.868592.1541103.2631QC'd by Selleck
Cytotoxic0.417694.690582Complete curve; high efficacy-6.37922.18760.986124.3029118.9934-1.10 0 0 0 0 0 0 0 0 0 021.4583113.0531121.9635115.8336128.0296109.3466109.274655.291834.103826.512620.023521.4583QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Mycobacterium tuberculosis
External ID: CHEMBL3123762
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2014
Volume: 74
First Page: 664
Last Page: 670
DOI: 10.1016/j.ejmech.2013.09.061

Target ChEMBL ID: CHEMBL360
ChEMBL Target Name: Mycobacterium tuberculosis
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=69.7%
Inhibition=96.3%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: s-my-keats_NCIH929-m4-1
Protocol: SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Cells; 5 uL; white, solid bottom 1536-well Greiner assay plate.
2; Compounds; 23 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head to transfer to the assay plates.
3; Incubation; 48 hours; 37C incubation.
4; Reagent;5uL; CellTiter Glo (Promega).
5; Detector; 425V; Luminescence; Viewlux PerkinElmer.

NOTES (numbers refer to Sequence numbers above)
1. The cell-based screening methods employed in this study were like those previously published [1]. Briefly, the corresponding myeloma cell lines were screened in 1,536-well plates with 500 cells, 5-uL per well for inhibition of cell viability (assessed by measuring ATP levels with CellTiterGlo).
2. NCATS MIPE 4.0 library of approved and investigational drugs were added using the Kalypsis pin tool. Wells treated with DMSO only for 100% viability and media only for 0% viability were used as controls.
3. The assay plates were covered and incubated for 48 hours in a 37C, 5% CO2 incubator with controlled humidity.
4. After 48 hours, CellTilter-GloTM luminescent substrate mix (Promega) reagent was added to the assay plate and plates we incubated for 5 min at room temperature.
5. Signal was measured as median relative luminescence units on a ViewLux (PerkinElmer) multiplate reader.

Reference:
[1] Heske CM, Davis MI, Baumgart JT, Wilson K, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau DY, Guha R, Ferrer M, Arnaldez FI, Ji J, Tran HL, Zhang Y, Mendoza A, Helman LJ, Thomas CJ. Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. Clin Cancer Res. 2017 Dec 1;23(23):7301-7311. doi: 10.1158/1078-0432.CCR-17-1121. Epub 2017 Sep 12. PMID: 28899971; PMCID: PMC6636827.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Cytotoxic0.148296.190585Complete curve; high efficacy-6.82923.92950.992444.5048140.6953-1.10 0 0 0 0 0 0 0 0 0 037.5464136.9515141.9942144.5132137.0086139.274769.470850.205143.474741.413450.930437.5464QC'd by JohnsHopkins
Cytotoxic0.012983.536684Complete curve; high efficacy-7.89041.47870.997823.8147107.3513-1.10 0 0 0 0 0 0 0 0 0 023.9151110.1823102.343496.995170.752740.620228.6625.881524.655321.871925.213523.9151QC'd by Chemscene
Cytotoxic0.023592.464784Complete curve; high efficacy-7.62921.96730.956723.2254115.6902-1.10 0 0 0 0 0 0 0 0 0 04.0573111.7434116.8232109.391975.447232.990933.705930.026330.264932.170612.76854.0573QC'd by ChemieTek
Cytotoxic0.288175.880584Complete curve; high efficacy-6.54041.82650.968341.6685117.5491-1.10 0 0 0 0 0 0 0 0 0 036.3204119.5479107.4971113.5971126.3084112.3175118.484679.974545.966145.122348.307136.3204QC'd by Selleck
Cytotoxic0.295781.009684Complete curve; high efficacy-6.52923.19250.926140.4734121.483-1.10 0 0 0 0 0 0 0 0 0 011.322115.4342118.2478121.3497132.2979117.0883107.092749.913546.654851.648750.637411.322QC'd by Prestwick Chemical; Inc.
Cytotoxic0.2635116.509584Complete curve; high efficacy-6.57920.60.970641.249157.7585-1.10 0 0 0 0 0 0 0 0 0 040.8193148.2389152.8144145.5181150.8832117.900795.735582.368280.769561.721251.108540.8193QC'd by Toronto Research
Cytotoxic0.052688.20883Complete curve; high efficacy-7.27921.28760.994223.4223111.6302-1.10 0 0 0 0 0 0 0 0 0 017.5003110.0308111.5061103.845494.601259.384438.839430.849224.832526.413122.221717.5003QC'd by LC Labs
Cytotoxic0.052675.902483Complete curve; high efficacy-7.27922.04790.973721.174997.0774-1.10 0 0 0 0 0 0 0 0 0 018.3476101.803486.025499.482590.080350.384429.228830.857823.374816.245614.543118.3476QC'd by Tocris
Cytotoxic0.052679.925683Complete curve; high efficacy-7.27921.37230.966323.9977103.9232-1.10 0 0 0 0 0 0 0 0 0 017.613998.4232100.1087114.286377.500461.650832.015431.605425.732323.840827.908417.6139QC'd by SynKinase
Cytotoxic0.020990.480783Complete curve; high efficacy-7.67920.90.977517.1515107.6322-1.10 0 0 0 0 0 0 0 0 0 06.471996.9766103.361585.574958.317441.067631.175422.007623.02321.414419.28116.4719QC'd by Selleck
Cytotoxic0.005393.642383Complete curve; high efficacy-8.279210.969714.5291108.1714-1.10 0 0 0 0 0 0 0 0 0 08.149699.284981.998249.133631.068631.287422.589621.209613.435211.247510.25858.1496QC'd by SynKinase
Cytotoxic0.014894.690583Complete curve; high efficacy-7.82921.17050.98217.423112.1135-1.10 0 0 0 0 0 0 0 0 0 012.0947103.9614109.053682.852955.000727.887130.356624.600918.123514.68813.793112.0947QC'd by SynKinase
Cytotoxic0.093596.642483Complete curve; high efficacy-7.02921.66040.992224.5734121.2158-1.10 0 0 0 0 0 0 0 0 0 025.6091121.7166119.6038122.5533110.023190.71841.660937.931622.388222.677922.400325.6091QC'd by Selleck
Cytotoxic0.046982.967883Complete curve; high efficacy-7.32924.95490.917922.6763105.644-1.10 0 0 0 0 0 0 0 0 0 02.6388101.9106107.1814103.9277109.288434.581138.965938.548133.351423.30352.61952.6388QC'd by NCI
Cytotoxic0.0296105.787183Complete curve; high efficacy-7.52920.50.883422.0136127.8007-1.10 0 0 0 0 0 0 0 0 0 04.7056117.0952117.3948102.779158.640855.617851.251852.864946.062539.792825.44594.7056QC'd by Selleck
Cytotoxic0.0209126.334483Complete curve; high efficacy-7.67920.80.98917.1119143.4463-1.10 0 0 0 0 0 0 0 0 0 016.0678134.7593122.167111.586876.247354.666237.345223.48931.102310.658718.953916.0678QC'd by Tocris
Cytotoxic0.0074100.270383Complete curve; high efficacy-8.12922.04790.993616.8213117.0916-1.10 0 0 0 0 0 0 0 0 0 023.4575117.6101105.197473.040125.850513.91814.847215.041116.016216.504218.359623.4575QC'd by Selleck
Cytotoxic0.0235108.888982Complete curve; high efficacy-7.62920.70.99411.7255120.6144-1.10 0 0 0 0 0 0 0 0 0 013.4791114.531297.322186.143674.13546.996429.785423.38115.47313.144913.473313.4791QC'd by BIOMOL
Cytotoxic0.0235110.59682Complete curve; high efficacy-7.62921.62660.976412.0566122.6526-1.10 0 0 0 0 0 0 0 0 0 012.2889128.4612120.246294.57586.24920.741516.111913.685812.951413.59113.568112.2889QC'd by FLUKA
Cytotoxic0.041884.248182Complete curve; high efficacy-7.37920.80.942513.632697.8807-1.10 0 0 0 0 0 0 0 0 0 06.907782.5934102.65586.90856441.11432.79328.119227.818519.73737.48046.9077QC'd by Otava
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Mycobacterium tuberculosis
External ID: CHEMBL3123763
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2014
Volume: 74
First Page: 664
Last Page: 670
DOI: 10.1016/j.ejmech.2013.09.061

Target ChEMBL ID: CHEMBL360
ChEMBL Target Name: Mycobacterium tuberculosis
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=95.6%
Inhibition=97.7%
Inhibition=90%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:D-alanine--D-alanine ligase B
External ID: CHEMBL1220494
Protocol: N/A
Comment: Journal: Nat. Chem. Biol.
Year: 2009
Volume: 5
Issue: 11
First Page: 849
Last Page: 856
DOI: 10.1038/nchembio.221

Target ChEMBL ID: CHEMBL1956
ChEMBL Target Name: D-alanylalanine synthetase
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard UnitsActivity Comment
Inhibition%Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Iron-sulfur cluster insertion protein ErpA
External ID: CHEMBL1220493
Protocol: N/A
Comment: Journal: Nat. Chem. Biol.
Year: 2009
Volume: 5
Issue: 11
First Page: 849
Last Page: 856
DOI: 10.1038/nchembio.221

Target ChEMBL ID: CHEMBL3309017
ChEMBL Target Name: Iron-sulfur cluster insertion protein ErpA
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard UnitsActivity Comment
Inhibition%Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Cell division protein FtsA
External ID: CHEMBL1220492
Protocol: N/A
Comment: Journal: Nat. Chem. Biol.
Year: 2009
Volume: 5
Issue: 11
First Page: 849
Last Page: 856
DOI: 10.1038/nchembio.221

Target ChEMBL ID: CHEMBL3309010
ChEMBL Target Name: Cell division protein FtsA
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard UnitsActivity Comment
Inhibition%Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:D-alanine--D-alanine ligase B
External ID: CHEMBL1220509
Protocol: N/A
Comment: Journal: Nat. Chem. Biol.
Year: 2009
Volume: 5
Issue: 11
First Page: 849
Last Page: 856
DOI: 10.1038/nchembio.221

Target ChEMBL ID: CHEMBL1956
ChEMBL Target Name: D-alanylalanine synthetase
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard UnitsActivity Comment
Inhibition%Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Iron-sulfur cluster insertion protein ErpA
External ID: CHEMBL1220508
Protocol: N/A
Comment: Journal: Nat. Chem. Biol.
Year: 2009
Volume: 5
Issue: 11
First Page: 849
Last Page: 856
DOI: 10.1038/nchembio.221

Target ChEMBL ID: CHEMBL3309017
ChEMBL Target Name: Iron-sulfur cluster insertion protein ErpA
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard UnitsActivity Comment
Inhibition%Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Cell division protein FtsA
External ID: CHEMBL1220507
Protocol: N/A
Comment: Journal: Nat. Chem. Biol.
Year: 2009
Volume: 5
Issue: 11
First Page: 849
Last Page: 856
DOI: 10.1038/nchembio.221

Target ChEMBL ID: CHEMBL3309010
ChEMBL Target Name: Cell division protein FtsA
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard UnitsActivity Comment
Inhibition%Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1280810
Protocol: N/A
Comment: Journal: Antimicrob. Agents Chemother.
Year: 2008
Volume: 52
Issue: 8
First Page: 2923
Last Page: 2925
DOI: 10.1128/aac.00273-08

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard Value
FC=3.41
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: ERR513
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-8.61372.09370.7210-9.347240 0 0 0 0 0 0 0-1.1981-7.7893-1.3061-0.91362.7218-2.44492.34910.5984-1.1981QC'd by EnamineInactive0004-2.1799-5.7621-6.6695
Inactive0-5.76374.95490.7632-7.8669040 0 0 0 0 0 0 0-9.70720.11940.8287-2.1801-1.25493.4297-9.8891-4.5089-9.7072QC'd by EnamineInactive0-4.21373.24750.7579-22.3272-240 0 0 0 0 0 0 0-18.1894-7.6164-4.6343
Cytotoxic48.557732.580620Single point of activity-4.31373.29750.9389-34.0806-1.5-30 0 0 0 0 0 0 0-30.48392.00771.2353-4.12-5.6743-2.5921-0.0827-2.7826-30.4839QC'd by EnamineInactive0-4.46372.90230.9774-26.7175-0.540 0 0 0 0 0 0 0-25.1812-1.37171.1119
Inactive0004-4.0244-1.58150.55321.86960.2877-1.0948-0.97181.3168-4.0244QC'd by EnamineInactive00042.6212-1.36331.1082
Inactive0-4.313710.6075-12.9835-1.540 0 0 0 0 0 0 0-9.1529-6.26020.8875-0.2672-1.0757-1.1078-3.3998-4.2513-9.1529QC'd by SIGMAInactive0-4.16374.44950.8449-13.8135-140 0 0 0 0 0 0 0-11.0946-2.2814-1.8218
Inactive0004-2.2635-3.2218-1.5002-3.2094-6.5467-6.9838-9.2586-2.3579-2.2635QC'd by SIGMAInactive0004-2.1934-6.1949-2.9926
Inactive0004-3.6053-10.98-3.1918-5.1884-6.2628-0.9809-3.7687-3.2149-3.6053QC'd by SIGMAInactive0004-2.2311-5.3121.6461
Cytotoxic48.557749.883420Single point of activity-4.31373.29750.9731-52.7952-2.9118-30 0 0 0 0 0 0 0-47.5721-5.7276-1.70880.07121.5459-4.3172-5.7565-4.7314-47.5721QC'd by SIGMACytotoxic68.589655.54720Single point of activity-4.16373.990.9932-57.6622-2.1152-30 0 0 0 0 0 0 0-44.4411-3.0449-2.577
Inactive0-6.36370.20.60998-9.656340 0 0 0 0 0 0 05.2888-8.0469-2.15330.5824-6.7160.56390.89561.59855.2888QC'd by SIGMAInactive0-5.26371.22210.9111-12.426240 0 0 0 0 0 0 15.0335-0.8992.8828
Inactive0-4.16374.44950.8402-12.6467040 0 0 0 0 0 0 0-10.1223-1.34671.9663-1.54012.2503-0.6504-1.39571.3844-10.1223QC'd by SIGMAInactive0004-5.9601-4.8718-1.2894
Inactive0-7.06374.95490.7513-8.96612.540 0 0 0 0 0 0 0-15.38840.7062.90453.3353-8.2144-8.9894-9.0163-3.1514-15.3884QC'd by SIGMAInactive0-4.36373.62720.923-19.77080.540 0 0 0 0 0 0 0-18.5592.3106-3.7006
Cytotoxic43.277175.632420Single point of activity-4.36373.29750.9904-76.4078-0.7754-30 0 0 0 0 0 0 0-70.38471.99022.3693-0.9536-1.7116-0.7698-5.276-6.3803-70.3847QC'd by SIGMACytotoxic48.557782.719420Single point of activity-4.31373.29750.9843-85.6388-2.9194-30 0 0 0 0 0 0 0-76.6203-7.7845-4.8132
Inactive0-4.41370.70.7291-12.603140 0 0 0 0 0 0 0-8.83580.5447-0.27422.49020.87441.9273-4.8205-1.4703-8.8358QC'd by SIGMAInactive0004-3.8112-0.6122-0.8775
Inactive0004-4.7292-2.4847-4.1876-6.48671.0395-0.71620.0299-0.793-4.7292QC'd by SIGMAInactive00042.63140.3943-1.3136
Inactive0-5.81371.64360.80470.5-6.497440 0 0 0 0 0 0 0-0.4266-9.1645-5.8022-3.6937-7.1147-4.6312-0.94771.1703-0.4266QC'd by SIGMAInactive0-4.31374.50450.829513.5-1.965340 0 0 0 0 0 0 012.7252-3.68221.1451
Cytotoxic24.336549.095240Partial curve; partial efficacy-4.61374.50450.9503-50.0798-0.9846-2.20 0 0 0 0 0 0 0-50.0782-0.0272.3579-4.7322-0.13674.7681-8.001-12.0828-50.0782QC'd by SIGMACytotoxic34.376251.39520Partial curve; partial efficacy-4.46371.66040.9408-52.4652-1.0701-2.20 0 0 0 0 0 0 0-46.02210.25280.4999
Inactive0-5.86374.95490.5635-7.1429-140 0 0 0 0 0 0 11.7155-3.0936-3.86271.08310.1892-0.7274-10.5357-4.05151.7155QC'd by LightBiologicalsInactive00041.3344-8.4864-3.5514
Inactive0-8.01374.95490.8219-1.5-15.383740 0 0 0 0 0 0 0-0.1642-15.3198-14.49810.2013-6.9242.4229-4.18230-0.1642QC'd by SIGMAInactive0-5.01374.95490.41315-2.544240 0 0 0 0 0 0 03.88070.31652.8847
Inactive0-7.96374.95490.6746-2.3322740 0 0 0 0 0 0 17.57815.96367.5271-8.1935-0.710.9919-1.6782-0.86047.5781QC'd by SIGMAInactive0-6.11372.72020.84876-3.067540 0 0 0 0 0 0 06.1795-3.1652-6.3062
Cytotoxic43.277130.71920Partial curve; partial efficacy; poor fit-4.36371.46410.9032-33.219-2.5-2.40 0 0 0 0 0 0 0-27.6825-1.9081-4.6287-2.873-0.37610.9727-8.0988-6.6948-27.6825QC'd by SIGMAInactive0-4.76371.88510.9867-25.4518-0.540 0 0 0 0 0 0 0-24.5432-1.7780.5931
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR845
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-6.71373.990.74483.5-3.097940 0 0 0 0 0 0 1-4.53010.5359-3.9754-6.3316-1.5343.70283.02253.9166-4.5301QC'd by EnamineInactive0-4.36374.50450.860920.5-2.001440 0 0 0 0 0 0 019.79981.4656-7.5012
Inhibitor38.570835.180610Partial curve; partial efficacy; poor fit-4.41370.30.5495-40.7918-5.6112-2.40 0 0 0 0 0 0 0-30.6598-14.2189-5.7598-1.3427-19.1905-11.1974-18.7235-15.3163-30.6598QC'd by EnamineInactive0-8.76374.95490.5011-5.7381240 0 0 0 0 0 0 0-4.77690.9052-7.1733
Inhibitor43.277177.03210Single point of activity-4.36373.29750.9971-78.3429-1.3109-30 0 0 0 0 0 0 0-72.2295-0.848-0.118-4.2082-0.6518-1.8942-0.08-5.3518-72.2295QC'd by EnamineInhibitor43.277163.648410Single point of activity-4.36372.95230.9946-65.7144-2.0659-30 0 0 0 0 0 0 0-59.6321-2.31811.0274
Inactive0-4.61374.0950.7785-11.2649040 0 0 0 0 0 0 0-11.05412.37760.40940.2158-4.58290.01091.9949-2.9254-11.0541QC'd by EnamineInactive0-4.41373.92950.7033-11.88-140 0 0 0 0 0 0 0-11.56670.6312.2683
Inhibitor13.685430.707521Partial curve; partial efficacy-4.86371.3310.9362-34.9705-4.2631-2.20 0 0 0 0 0 0 0-32.0588-3.9769-3.3008-9.2624-0.6359-6.9717-5.8106-24.2995-32.0588QC'd by SIGMAInhibitor19.331244.710720Partial curve; partial efficacy-4.71374.95490.9424-44.06730.6434-2.20 0 0 0 0 0 0 0-43.91873.3929-7.8909
Inactive0-4.61370.50.86281.139-21.207340 0 0 0 0 0 0 0-4.0509-23.9228-19.6932-21.9663-17.0189-16.3805-16.3485-13.4943-4.0509QC'd by SIGMAInactive0-4.56370.60.86232.9723-21.743540 0 0 0 0 0 0 0-2.5231-21.0888-19.8358
Inactive0-4.66374.0950.7922-16.0186740 0 0 0 0 0 0 0-15.43222.495111.00468.413812.5339-0.02468.6463-1.6168-15.4322QC'd by SIGMAInactive0-4.16374.95490.6395-12.122540 0 0 0 0 0 0 0-8.851710.91192.0118
Inhibitor43.277176.013310Single point of activity-4.36373.29750.9556-72.62463.3888-30 0 0 0 0 0 0 0-67.00170.43212.27294.102815.2231-2.70330.1771-0.4468-67.0017QC'd by SIGMAInhibitor68.589678.061510Single point of activity-4.16374.95490.8832-73.18654.8751-30 0 0 0 0 0 0 0-58.3846-2.614-4.3734
Activator1.219732.68440Complete curve; partial efficacy; poor fit-5.91370.80.948130.5-2.18441.40 0 0 0 0 0 0 029.0103-1.64831.5958-4.32031.836314.835216.647829.69429.0103QC'd by SIGMAActivator48.557744.5940Single point of activity-4.313710.538947.78773.193730 0 0 0 0 0 0 038.027214.7051.0969
Inactive0-4.61374.0950.9713-21.2654-1.540 0 0 0 0 0 0 0-21.0545-2.7301-0.41341.0029-2.2409-1.0812-2.1276-6.3156-21.0545QC'd by SIGMAInactive0-4.41373.990.8429-24.48221.540 0 0 0 0 0 0 0-23.7352-0.6662-2.5056
Activator17.2289133.59920Partial curve; high efficacy-4.76371.55790.9975127.2961-6.30312.10 0 0 0 0 0 0 0117.8667-8.9515-6.7202-3.1268-8.6465-1.68023.809264.311117.8667QC'd by SIGMAActivator21.6899164.62480Partial curve; high efficacy-4.66371.24750.9927156.6074-8.01742.10 0 0 0 0 0 0 0133.1695-7.9286-14.0417
Inhibitor68.589698.74510Single point of activity-4.16374.95490.931-122.9328-24.1879-30 0 0 0 0 0 0 0-104.5347-33.7189-31.4897-29.5277-32.0771-19.6494-24.4139-12.4858-104.5347QC'd by SIGMAInhibitor68.589665.97810Single point of activity-4.16374.44950.9656-93.0438-27.0659-30 0 0 0 0 0 0 0-79.0031-29.1044-30.014
Inactive0-4.11374.95490.6653-23.47291.540 0 0 0 0 0 0 0-16.22742.7934.6828-5.1704-5.88253.40514.4085.1222-16.2274QC'd by SIGMAInactive0004-8.3878-2.7507-9.7834
Inactive0-6.96374.50450.52725-3.781740 0 0 0 0 0 0 012.2006-2.9898-3.919-4.81813.02829.0156-2.12881.783312.2006QC'd by SIGMAInactive0-4.61374.95490.8110.5-1.339640 0 0 0 0 0 0 010.67871.3266-2.2209
Inactive0-4.81370.50.790222-1.879740 0 0 0 0 0 0 016.0881-1.9337-0.9491-0.2665-4.06648.70261.96710.79316.0881QC'd by SIGMAInactive0-4.81371.78850.535915.5-0.482940 0 0 0 0 0 0 014.811-5.402411.5478
Activator5.448365.90960Complete curve; high efficacy-5.26373.51170.992865.1288-0.78081.10 0 0 0 0 0 0 064.12783.4298-0.9076-4.3967-2.59521.436710.934765.698664.1278QC'd by SIGMAActivator8.6349121.11690Partial curve; high efficacy-5.06371.17050.9968115.9495-5.16742.10 0 0 0 0 0 0 0108.5669-5.4351-5.5745
Inactive0-5.71374.95490.595-8.7497040 0 0 0 0 0 0 15.4059-2.6152-3.8122-2.09634.4994.406-9.7914-7.14735.4059QC'd by LightBiologicalsInactive0-4.11374.95490.3408-10.3215040 0 0 0 0 0 0 0-7.3513-4.35072.8856
Inactive0-7.31371.22210.9525-1.4634-23.351240 0 0 0 0 0 0 1-12.6292-20.3271-25.7094-13.6954-6.9291-1.6842-1.5865-0.8028-12.6292QC'd by SIGMAInactive0-6.96372.40640.4996-15.2703040 0 0 0 0 0 0 0-27.72521.4691-2.4748
Activator5.448383.66690Complete curve; high efficacy; poor fit-5.263710.969688.03014.36321.31 0 0 0 0 0 0 082.872636.415612.07881.2155-2.961220.571436.413270.139882.8726QC'd by SIGMAActivator5.4483159.39970Partial curve; high efficacy-5.26370.50.9946149.0275-10.37222.10 0 0 0 0 0 0 0117.16-5.2091-4.8857
Inhibitor68.589652.742510Single point of activity-4.16374.95490.7907-52.540.2025-30 0 0 0 0 0 0 0-42.826-0.156510.14883.0709-2.1032-5.5467-13.87819.2268-42.826QC'd by SIGMAInhibitor68.589648.042810Single point of activity-4.16374.95490.7805-49.2366-1.1938-30 0 0 0 0 0 0 0-40.11641.4546-2.3883
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: PGC981
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-4.86371.47810.785.5-8.060740 0 0 0 0 0 0 04.915-11.7172-10.2261-5.6747-3.2162-8.4895-6.42940.12124.915QC'd by EnamineInactive0-4.71374.95490.71496.5-4.107540 0 0 0 0 0 0 06.3707-4.6171-5.2048
Inactive0-6.66374.95490.6015-3.7977240 0 0 0 0 0 0 0-5.28490.7910.92684.1721.3686-5.48181.3153-6.0814-5.2849QC'd by EnamineInactive0-5.81374.95490.3563-3.9449240 0 0 0 0 0 0 0-7.65024.16730.1723
Cytotoxic0.769679.126986Complete curve; high efficacy-6.11372.40640.989-80.2129-1.086-1.10 0 0 0 0 0 0 0-74.1102-5.396-2.9033-0.44662.7921-36.8956-82.6325-83.0675-74.1102QC'd by EnamineCytotoxic0.685977.815120Complete curve; high efficacy; poor fit-6.16372.40640.9961-79.552-1.7369-1.31 0 0 0 0 0 0 0-75.8034-72.1781-1.7358
Inactive0004-3.6673-6.0811-7.2954-2.9298-5.4835-6.4501-0.8482-0.7681-3.6673QC'd by EnamineInactive00041.9261-2.3973-1.7209
Inactive00043.10533.4072-1.20312.5309-0.51780.13742.52470.33163.1053QC'd by SIGMAInactive00040.58950.0467-1.1307
Inactive0-8.81374.95490.3082-4.4311740 0 0 0 0 0 0 0-0.12874.6299-9.52591.88571.5028-8.8402-7.8944-7.173-0.1287QC'd by SIGMAInactive0-7.21374.95490.6151-5.42113.540 0 0 0 0 0 0 13.27414.48891.0958
Inactive0-4.11374.95490.5878-11.9248-140 0 0 0 0 0 0 0-8.6874-2.6017-2.1396-4.8238-0.7809-0.22621.32562.5681-8.6874QC'd by SIGMAInactive0004-3.0350.9522-1.0902
Cytotoxic24.336546.215220Partial curve; partial efficacy-4.61374.0950.8819-45.84720.3681-2.20 0 0 0 0 0 0 0-45.43845.881-8.1203-9.15891.98714.56915.5262-10.7271-45.4384QC'd by SIGMACytotoxic34.376235.963320Partial curve; partial efficacy; poor fit-4.46371.10.6483-38.4633-2.5-2.40 0 0 0 0 0 0 0-30.38613.9144-10.9322
Inactive0-6.71373.990.8426-7.88744.540 0 0 0 0 0 0 0-2.89953.23475.85414.84131.1609-11.9895-9.9614-6.4748-2.8995QC'd by SIGMAInactive0-6.21374.95490.3993-9.8085-140 0 0 0 0 0 0 1-4.23611.05812.2314
Inactive0004-8.8762-5.923-4.3846-2.7844-3.0174-1.57820.44671.6153-8.8762QC'd by SIGMAInactive0004-2.6033-0.7522-0.3781
Cytotoxic13.685431.192220Partial curve; partial efficacy; poor fit-4.86374.0950.987-28.69222.5-2.40 0 0 0 0 0 0 0-29.32691.0510.82913.02485.19882.44540.8952-21.0544-29.3269QC'd by SIGMACytotoxic30.637939.175420Single point of activity-4.51372.63840.9942-36.67542.5-30 0 0 0 0 0 0 0-33.8452.13522.347
Cytotoxic38.570879.766740Partial curve; high efficacy-4.41372.63840.9853-84.0115-4.2449-2.10 0 0 0 0 0 0 0-76.5239-2.4554-4.41340.9249-10.1622-3.8808-5.616-14.7247-76.5239QC'd by SIGMACytotoxic54.482785.061720Single point of activity-4.26373.24750.9911-91.6046-6.5429-30 0 0 0 0 0 0 0-78.4884-7.7514-8.9605
Cytotoxic19.331237.87620Partial curve; partial efficacy-4.71371.62590.9556-35.95541.9206-2.20 0 0 0 0 0 0 0-33.29621.1258-0.21948.2922-0.93250.73450.067-16.4636-33.2962QC'd by SIGMACytotoxic24.336537.729420Single point of activity-4.61374.95490.9857-38.7294-1-30 0 0 0 0 0 0 0-38.4602-3.9414-2.1898
Inactive0004-2.46990.42311.17392.4494-2.3903-5.8621-2.75422.1121-2.4699QC'd by SIGMAInactive0004-2.214-1.4625-2.7485
Inactive0-4.66374.0950.741112.5-2.679940 0 0 0 0 0 0 012.3306-2.456-4.37830.7114-1.00270.4255-9.31662.996712.3306QC'd by SIGMAInactive0-4.16374.95490.944819.50.267340 0 0 0 0 0 0 015.7501-0.36041.1005
Cytotoxic24.336530.069120Single point of activity-4.61374.0950.9268-30.5691-0.5-30 0 0 0 0 0 0 0-30.4742-6.1565-0.15064.9067-0.89490.097-0.2413-8.1828-30.4742QC'd by SIGMACytotoxic30.637941.734320Single point of activity-4.51373.29750.9593-36.23435.5-30 0 0 0 0 0 0 0-33.40166.88037.6192
Inactive0-5.86370.40.90196.5-8.152440 0 0 0 0 0 0 04.1776-6.9275-6.6426-8.0437-2.1876-0.6978-1.40723.42914.1776QC'd by LightBiologicalsInactive00046.6773-1.88140.4883
Inactive0-4.61374.50450.9231100.077740 0 0 0 0 0 0 010.0385-0.48612.253-0.50310.15970.9668-0.76862.389210.0385QC'd by SIGMAInactive00047.4959-0.5175-0.4627
Inconclusive0.153632.691210Partial curve; partial efficacy; poor fit-6.81370.20.930116-16.69122.40 0 0 0 0 0 0 011.0017-10.576-3.6335-2.6864-0.78383.31442.74056.346611.0017QC'd by SIGMAInactive0-5.01371.75290.63996.5-1.856440 0 0 0 0 0 0 06.2964-1.41730.4366
Cytotoxic48.557732.238220Partial curve; partial efficacy; poor fit-4.31371.10.9013-36.0152-3.7769-2.40 0 0 0 0 0 0 0-26.6793-0.5468-5.0549-6.9535-0.2308-5.7352-8.0532-10.5038-26.6793QC'd by SIGMAInactive0-4.61371.46410.9003-22.7063-2.914740 0 0 0 0 0 0 0-20.1719-4.0675-2.6739
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC428
Protocol: Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive00042.40140.97590.30781.8904-1.32141.1138-1.6886-2.57882.4014QC'd by EnamineInactive00042.2787-0.9694-3.8908
Inactive0004-2.9424-0.1831-2.1441-0.81230.7356-2.795-3.3133-0.3073-2.9424QC'd by EnamineInactive00041.5663-0.9898-2.1656
Inhibitor1.933130.25050Complete curve; partial efficacy-5.71374.95490.9884-32.7505-2.5-1.20 0 0 0 0 0 0 0-32.7088-2.9131-4.6477-3.9229-1.60220.1764-32.5182-31.28-32.7088QC'd by EnamineInhibitor2.16935.34080Complete curve; partial efficacy; poor fit-5.66374.95490.9534-35.28250.0583-1.41 0 0 0 0 0 0 0-36.4368-31.3574-4.1999
Inactive00044.2421-5.00691.1218-0.01471.4143-0.7153-1.8654-1.08794.2421QC'd by EnamineInactive0004-2.4793-2.9079-3.184
Inactive0-4.21373.990.5455-9.5512040 0 0 0 0 0 0 0-7.9593-4.54884.51660.2512-0.7312-1.48191.47-0.0426-7.9593QC'd by SIGMAInactive0004-11.2315-5.6697-2.8914
Inactive0004-4.1758-2.8245-1.44510.5422-0.3307-1.02441.9480.1256-4.1758QC'd by SIGMAInactive00041.6001-3.85641.804
Inactive00044.3768-4.084-2.0739-1.1987-0.2477-0.4857-0.73983.08794.3768QC'd by SIGMAInactive00043.4197-0.1470.119
Inactive0-4.41374.0450.787-9.44140 0 0 0 0 0 0 0-9.1167-0.88074.7479-0.5740.36761.5356-0.56610.5529-9.1167QC'd by SIGMAInactive0-4.16374.95490.9155-18.8168-0.540 0 0 0 0 0 0 0-15.264-3.64431.0791
Inactive00044.56840.73691.2152-0.4642-5.3740.7893-5.2966-0.6674.5684QC'd by SIGMAInactive00043.07711.5072-1.0121
Inactive00045.87980.9788-0.8043-0.16830.5835-0.00870.8357-0.43085.8798QC'd by SIGMAInactive00043.0034.6097-0.2019
Inactive0-4.71370.9310.966716-12.66240 0 0 0 0 0 0 011.1718-11.0163-13.0889-15.135-12.7909-8.7096-8.71320.854911.1718QC'd by SIGMAInactive0-4.66374.0950.96819-8.276140 0 0 0 0 0 0 018.8245-9.1995-8.5885
Inactive0-4.16374.95490.9451-31.7539-2.540 0 0 0 0 0 0 0-26.4616-3.7295-5.2291-3.0969-2.288-3.5247-2.32081.7484-26.4616QC'd by SIGMAInactive0-4.16374.95490.9334-30.6082-2.540 0 0 0 0 0 0 0-25.5069-2.7103-5.3426
Inactive0-4.71374.95490.9407-8.8985040 0 0 0 0 0 0 0-9.08210.3128-1.43780.2924-0.419201.586-4.053-9.0821QC'd by SIGMAInactive0-4.51370.80.6738-13.3555140 0 0 0 0 0 0 0-9.46290.6379-2.0412
Inactive0-8.41370.70.5837-1.07391040 0 0 0 0 0 0 00.29827.47482.23922.15450.68180.246-6.31161.35580.2982QC'd by SIGMAInactive0-6.91374.95490.486-0.784640 0 0 0 0 0 0 00.21723.73181.5014
Inactive0004-2.40140.9093-2.3514-1.26-1.532-1.0946-1.4276-1.3037-2.4014QC'd by SIGMAInactive0004-0.9775-6.6823-0.2967
Activator12.197242.828241Complete curve; partial efficacy-4.91372.95230.987642.7435-0.08481.20 0 0 0 0 0 0 042.6198-2.2542-2.3630.4008-0.30113.44693.268732.944442.6198QC'd by SIGMAActivator15.355343.419221Partial curve; partial efficacy-4.81371.46410.904646.68233.26312.20 0 0 0 0 0 0 043.806214.88091.3724
Inactive00041.3627-0.0701-2.08231.36830.09830.2791.0733-2.83051.3627QC'd by LightBiologicalsInactive0004-0.91481.1123-2.0113
Inactive0-4.61374.0950.936610-2.575240 0 0 0 0 0 0 09.8552-1.1769-2.1967-4.1352-1.5482-4.2293-3.65290.53249.8552QC'd by SIGMAInactive0-4.16374.95490.901717.5-2.621540 0 0 0 0 0 0 013.8866-3.2503-5.5179
Activator7.695944.941241Complete curve; partial efficacy-5.11371.75290.977743.3726-1.56861.20 0 0 0 0 0 0 042.7055-6.7239-3.17491.0732-2.18933.30557.112735.965142.7055QC'd by SIGMAActivator30.637938.378610Partial curve; partial efficacy; poor fit-4.51370.90.890248.3786102.41 1 1 0 0 0 0 038.606523.46220.9144
Inactive0-5.81371.55790.9841-8.5398140 0 0 0 0 0 0 11.1671.751.36320.05350.9714-1.3806-6.7289-8.36651.167QC'd by SIGMAInactive0-5.51372.72020.8571-9.4462040 0 0 0 0 0 0 12.69632.31221.1111
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR136
Protocol: Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-4.51374.95490.98419.5-3.038640 0 0 0 0 0 0 019.3676-2.3612-2.8082-5.4488-2.2489-2.9112-3.4175-1.559219.3676QC'd by EnamineInactive0004-5.35172.0093-6.4777
Inhibitor48.557736.21060Partial curve; partial efficacy; poor fit-4.31370.90.8071-45.4474-9.2368-2.40 0 0 0 0 0 0 0-34.4298-9.7122-4.364-11.671-16.6813-9.6787-15.4098-16.2365-34.4298QC'd by EnamineInactive0004-11.0366-0.9734-7.3298
Inhibitor43.277183.00920Single point of activity-4.36373.29750.9949-84.0538-1.0446-30 0 0 0 0 0 0 0-77.6923-3.87922.7538-2.3693-0.5727-1.6659-0.0681-5.2567-77.6923QC'd by EnamineInhibitor43.277179.45370Single point of activity-4.36372.95230.9963-81.306-1.8523-30 0 0 0 0 0 0 0-73.3378-0.46270.1851
Inactive0-4.46373.1320.7667-13.4494-140 0 0 0 0 0 0 0-12.8745-0.32052.0373-3.4545-4.74620.00971.7226-2.7713-12.8745QC'd by EnamineInactive0-4.31373.19250.8101-17.6246-240 0 0 0 0 0 0 0-15.9372-5.0774-4.5471
Inhibitor19.331245.63620Partial curve; partial efficacy-4.71374.95490.9167-45.62720.009-2.20 0 0 0 0 0 0 0-45.72563.2263-6.99944.18433.6048-8.45733.4843-19.3083-45.7256QC'd by SIGMAInhibitor21.689948.50050Partial curve; partial efficacy-4.66374.0950.955-49.3184-0.8179-2.20 0 0 0 0 0 0 0-48.9059-6.2148-3.7555
Inactive0-4.16371.1110.75881.2662-20.645940 0 0 0 0 0 0 0-7.6949-23.8716-19.2362-23.8279-16.4076-18.7298-19.3953-17.0738-7.6949QC'd by SIGMAInactive0-4.16371.53860.83570.58-19.195640 0 0 0 0 0 0 0-7.0166-20.3188-16.6054
Inactive0-4.66374.0950.806-16.89936.540 0 0 0 0 0 0 0-16.999410.73521.88666.048412.4092-0.01887.5808-1.5316-16.9994QC'd by SIGMAInactive0-4.16374.95490.883-20.90586.540 0 0 0 0 0 0 0-15.75492.18169.7822
Inhibitor43.277177.27130Single point of activity-4.36374.0950.9569-75.45791.8134-30 0 0 0 0 0 0 0-72.17882.6525-2.2372-1.501514.6872-2.40990.1529-0.4232-72.1788QC'd by SIGMAInhibitor68.589681.50290Single point of activity-4.16374.95490.9901-81.48520.0177-30 0 0 0 0 0 0 0-66.2581-2.2615-3.7766
Activator4.85583010Complete curve; partial efficacy; poor fit-5.31370.70.85413441.40 0 0 0 0 0 0 029.44141.61752.942113.13381.613413.135714.4628.542729.4414QC'd by SIGMAActivator34.376255.960710Partial curve; partial efficacy; poor fit-4.46370.60.793556.35420.39352.40 0 0 0 0 0 0 042.9205-1.42611.3781
Inhibitor68.589634.50210Partial curve; partial efficacy; poor fit-4.16374.95490.973-35.5021-1-2.40 0 0 0 0 0 0 0-29.1684-3.6431-0.38770.690.44960.0486-2.95930.4695-29.1684QC'd by SIGMAInactive0-4.61374.0950.9877-26.8039-1.540 0 0 0 0 0 0 0-26.5033-0.4236-2.0019
Activator21.6899156.736741Partial curve; high efficacy-4.66371.64360.9965152.646-4.09072.10 0 0 0 0 0 0 0139.0219-7.688-5.9205-2.6984-6.44832.92063.305165.1579139.0219QC'd by SIGMAActivator21.6899162.56741Partial curve; high efficacy-4.66371.1110.9904149.6613-12.90572.10 0 0 0 0 0 0 0123.4829-22.2955-11.9211
Inhibitor68.5896112.34550Single point of activity-4.16374.95490.9828-132.1561-19.8107-30 0 0 0 0 0 0 0-111.2426-20.1826-20.8287-18.7981-28.0886-17.1914-20.5085-12.8968-111.2426QC'd by SIGMAInhibitor68.589686.73230Single point of activity-4.16374.44950.9873-113.865-27.1328-30 0 0 0 0 0 0 0-95.3644-28.9816-26.9911
Inactive0-7.66373.92950.7686-7.2282.540 0 0 0 0 0 0 0-11.02341.09824.1458-4.8418-4.8691-9.443-3.8914-6.5282-11.0234QC'd by SIGMAInactive0-4.16374.95490.651-27.8917-340 0 0 0 0 0 0 0-23.2431-6.656-9.2309
Inactive0-4.41371.3310.898714-3.05240 0 0 0 0 0 0 011.0873-2.5867-3.2326-5.0433-4.6999-1.27990.11610.26511.0873QC'd by SIGMAInactive0-4.36374.0450.886215-0.287740 0 0 0 0 0 0 014.36781.375-2.3231
Inactive0-6.16370.20.775424-16.551840 0 0 0 0 0 0 017.516-13.7932-1.0086-0.097-3.61628.21882.019310.451717.516QC'd by SIGMAInactive0-4.76371.37230.927516.5-1.30240 0 0 0 0 0 0 014.8217-2.0042-1.1245
Activator6.85978.349582Complete curve; high efficacy-5.16372.35310.993574.2594-4.091.10 0 0 0 0 0 0 074.1184-4.5486-4.6511-8.825-2.30471.465710.463767.365974.1184QC'd by SIGMAActivator10.8707114.427843Partial curve; high efficacy-4.96371.47810.9985115.03150.60372.10 0 0 0 0 0 0 0113.44331.03430.5738
Inactive0-6.51374.95490.5499-7.6782040 0 0 0 0 0 0 1-1.3248-6.98861.92394.42461.2121-9.7318-6.8313-5.9944-1.3248QC'd by LightBiologicalsInactive0004-8.6845-1.797-2.7987
Inactive0-5.41370.80.90046-18.099440 0 0 0 0 0 0 1-21.7232-17.1597-21.7495-14.3887-17.1525-11.21-8.4462.3181-21.7232QC'd by SIGMAInactive0-5.21372.09370.8981-0.2998-16.214240 0 0 0 0 0 0 1-31.9687-17.1088-15.6886
Activator7.6959120.525544Partial curve; high efficacy-5.11370.70.9928114.4923-6.03322.10 0 0 0 0 0 0 096.374-4.3635-4.0674-6.7463-2.631320.309836.671572.031796.374QC'd by SIGMAActivator21.6899154.602341Partial curve; high efficacy-4.66370.70.9681162.64828.04592.11 0 0 0 0 0 0 0124.921836.981711.0863
Inhibitor68.589653.68390Single point of activity-4.16374.95490.8843-56.1458-2.4619-30 0 0 0 0 0 0 0-46.1475-3.3066-1.056-2.431-2.1781-4.9409-11.84398.4719-46.1475QC'd by SIGMAInhibitor68.589653.39790Single point of activity-4.16373.990.8078-57.5482-4.1503-30 0 0 0 0 0 0 0-45.11221.3906-2.0624
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Mycobacterium tuberculosis
External ID: CHEMBL3119863
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Eur J Med Chem
Year: 2014
Volume: 73
First Page: 243
Last Page: 249
DOI: 10.1016/j.ejmech.2013.12.013

Target ChEMBL ID: CHEMBL360
ChEMBL Target Name: Mycobacterium tuberculosis
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.18IC50=180nM
13.49IC90=13490nM
12.47IC50=12470nM
1.56IC50<1560nM
32.79IC90=32790nM
0.08IC90=80nM
0.07IC50=70nM
0.02IC90=20nM
0.02IC50=20nM
100IC90>100000nM
73.41IC50=73410nM
100IC90>100000nM
100IC50>100000nM
100IC90>100000nM
100IC50>100000nM
100IC90>100000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC756
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-7.86374.95490.4691-10.890740 0 0 0 0 0 0 08.2951-3.5934-17.82563.728-3.3143-3.1544-3.41174.3528.2951QC'd by EnamineInactive0-5.91374.95490.48948.51.175740 0 0 0 0 0 0 08.48355.7-2.2368
Inactive0-7.21374.95490.40832.5-6.308740 0 0 0 0 0 0 1-10.1762-3.3308-8.1739-6.92184.266411.9083-0.5284-5.8356-10.1762QC'd by EnamineInactive0-7.21374.95490.3691-6.9367-1.540 0 0 0 0 0 0 0-5.5669-7.1362-0.1385
Inhibitor1.9331113.210487Complete curve; high efficacy-5.71374.95490.9846-123.2827-10.0723-1.10 0 0 0 0 0 0 0-117.206-10.7699-22.4888-12.4254-6.51180.6162-122.7414-125.2872-117.206QC'd by EnamineInhibitor1.9331120.518410Complete curve; high efficacy; poor fit-5.71374.95490.9442-119.760.7584-1.31 0 0 0 0 0 0 0-113.3163-116.2959-15.8547
Inactive0-8.81374.95490.6276-1.5-23.330940 0 0 0 0 0 0 0-6.9561-18.60914.2346-0.05635.7534-2.7207-6.6784-4.0458-6.9561QC'd by EnamineInactive0-4.91374.95490.67133-13.282940 0 0 0 0 0 0 1-8.9666-10.8624-14.0596
Inhibitor48.557734.128310Partial curve; partial efficacy; poor fit-4.31371.59360.9877-48.5369-14.4086-2.40 0 0 0 0 0 0 0-39.4219-12.8405-14.8776-15.1051-14.86-12.8749-15.8706-20.1132-39.4219QC'd by SIGMAInhibitor68.589642.307610Single point of activity-4.16373.990.6044-42.24050.0671-30 0 0 0 0 0 0 0-32.3397-15.868116.9894
Inactive0-7.96374.95490.741.5-10.355940 0 0 0 0 0 0 1-15.0169-9.9531-10.71334.5939-1.7304-1.45467.6602-0.5767-15.0169QC'd by SIGMAInactive0004-14.859-13.2163-9.3098
Inactive0-6.51374.95490.59899-2.513340 0 0 0 0 0 0 011.69730.78462.1119-10.0111-3.685212.17340.718111.618411.6973QC'd by SIGMAInactive040 0 0 0 0 0 0 016.3373-14.8015-9.7381
Inhibitor68.589632.190510Partial curve; partial efficacy; poor fit-4.16374.95490.9333-32.19050-2.40 0 0 0 0 0 0 0-25.9921-0.75610.9798-0.51641.0571-2.5971-2.18895.2808-25.9921QC'd by SIGMAInhibitor54.482738.551110Single point of activity-4.26373.67720.7506-35.47323.0779-30 0 0 0 0 0 0 0-30.5241-3.270317.9183
Activator7.695932.09880Complete curve; partial efficacy; poor fit-5.11371.17050.89385.5-26.59881.40 0 0 0 0 0 0 03.0626-32.5823-21.1084-29.0917-26.3315-18.7973-20.4148-1.32993.0626QC'd by SIGMAInactive0-7.46374.50450.4143-10.33733.540 0 0 0 0 0 0 17.47462.66914.4156
Inactive0-8.81374.44950.581.039522.540 0 0 0 0 0 0 119.8217.5365-0.7335-0.826912.2606-2.48681.3946-4.133719.82QC'd by SIGMAInactive00044.4393-3.40321.9365
Activator9.688587.44380Partial curve; high efficacy-5.01371.1110.9835.4518-51.99212.10 0 0 0 0 0 0 031.4522-53.6971-45.0647-53.1956-58.3066-41.7857-30.32154.685831.4522QC'd by SIGMAActivator24.3365131.06770Partial curve; high efficacy-4.61371.13410.970482.8838-48.18392.10 0 0 0 0 0 0 060.7185-41.9229-50.2592
Inhibitor68.5896102.999410Single point of activity-4.16374.95490.9126-112.465-9.4656-30 0 0 0 0 0 0 0-93.2546-12.8632-27.0848-7.3454-8.8555-9.7568-7.97886.4016-93.2546QC'd by SIGMAInhibitor68.589685.608410Single point of activity-4.16374.95490.944-101.5037-15.8953-30 0 0 0 0 0 0 0-85.4409-16.1487-18.1915
Inhibitor21.689934.032910Partial curve; partial efficacy; poor fit-4.66371.47870.8531-36.5329-2.5-2.40 0 1 0 0 0 0 0-32.94412.3801-9.142323.5287-7.26264.059-6.3199-16.9462-32.9441QC'd by SIGMAInactive0-4.76373.92950.9033-24.5486040 0 0 0 0 0 0 0-24.62381.1616-5.4271
Inactive0-8.36370.60.5758-5.19734.497140 0 0 0 0 0 0 0-1.492426.08197.16867.27432.4662-0.9291-23.91225.1445-1.4924QC'd by SIGMAInactive0-6.06372.40640.6203-9.38677.540 0 1 0 0 0 0 1-0.299213.05514.9918
Inactive0-8.81374.95490.7618-4.635640 0 0 0 0 0 0 10.89323.8508-8.0292-4.7013-4.9681-1.7031-4.6863-4.9470.8932QC'd by SIGMAInactive0-6.16373.92950.60363-4.918140 0 0 0 0 0 0 1-8.3052-1.6572-3.0816
Activator9.6885153.03170Complete curve; high efficacy-5.01372.95230.9881152.6925-0.33921.10 0 0 0 0 0 0 0154.2348-8.4111-10.58393.4205-1.171512.040612.3376130.2412154.2348QC'd by SIGMAActivator13.6854129.32160Complete curve; high efficacy-4.86374.95490.9964137.38078.0591.11 0 0 0 0 0 0 0137.932449.111113.295
Inactive0-4.91374.95490.444-12.5490.540 0 0 0 0 0 0 15.8614-0.0331-9.32676.6938-0.25312.49384.0461-11.29095.8614QC'd by LightBiologicalsInactive0004-2.7991-4.8479-7.8846
Activator24.336541.70840Single point of activity-4.61374.0950.931932.657-9.051430 0 0 0 0 0 0 032.0784-3.5663-7.3386-15.2356-4.8834-11.4699-12.65141.923932.0784QC'd by SIGMAActivator48.557746.25170Single point of activity-4.31374.95490.885537.4014-8.850230 0 0 0 0 0 0 035.5314-6.6661-5.471
Activator6.1131159.82730Complete curve; high efficacy-5.21372.53340.9773152.783-7.04431.10 0 0 0 0 0 0 0153.3966-25.2204-14.08523.3931-8.592911.330526.7308143.426153.3966QC'd by SIGMAActivator24.336560.25150Partial curve; high efficacy; poor fit-4.61374.0950.6456118.703558.45192.30 0 0 0 0 0 0 0117.761480.334882.544
Inhibitor1.722939.472922Partial curve; partial efficacy-5.76371.41630.986-34.97294.5-2.20 0 0 0 0 0 0 14.48376.73975.89010.58273.8988-4.4773-25.2126-33.31084.4837QC'd by SIGMAInhibitor6.85939.386121Partial curve; partial efficacy-5.16370.80.943-41.2694-1.8833-2.20 0 0 0 0 0 0 18.8427-1.1528-2.3725
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1280999
Protocol: N/A
Comment: Journal: Antimicrob. Agents Chemother.
Year: 2008
Volume: 52
Issue: 8
First Page: 2923
Last Page: 2925
DOI: 10.1128/aac.00273-08

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard Value
FC=4.6
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: BPDCN-GEN22
Protocol: A total of 500 exponentially growing Gen2.2 cells were seeded per well in 5 uL of media (RPMI + Glutamine, without phenol red plus10% FBS and 1X Pen/Strep) into 1536-well solid white high base tissue culture treated Greiner One Bio Plates (789173-F), using a multidrop combi dispenser and a small sterile cassette. Compounds and controls totaling 23nL per well (negative control DMSO and positive control 9.2 uM Bortezomib-final) were immediately added to the plates using a 1536 head pin tool from Kalypsys. The plates were then covered with stainless steel gasket lids from Kalypsys and incubated for 48 hours at 37C under 95% relative humidity with 5% CO2. After 48 hours, the plates were removed and allowed to reach room temperature before 3 uL of Cell Titer Glo reagent (Promega) were added using an Aurora Flying Reagent Dispenser Bioraptor. The plates were then spun at 1000 rpms to remove bubbles and incubated for 15 minutes at room temperature before reading on a ViewLux using a luminescent filter with a 10 second exposure. The relative luciferase units were used to calculated percent activity using DMSO as 100% and Bortezomib as 0%.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Activator9.349537.11450Partial curve; high efficacy; poor fit-5.02924.50450.3394139.866102.75152.30 0 0 0 0 0 0 1 0 0 188.0524128.0096112.723388.625579.246188.4591116.5125107.434240.612105.1422136.374988.0524QC'd by BIOMOL
Activator05142.8394114.1417111.508167.841110.3078162.3881116.8787143.5866138.3617142.280496.0848142.8394QC'd by BIOMOL
Activator0.0066105.25930Complete curve; high efficacy; poor fit-8.17920.70.8893112.3492217.60861.30 0 1 0 0 0 0 0 0 0 1149.7744206.0416175.796299.9709145.4635125.3281120.2334135.1946115.4803122.261890.372149.7744QC'd by BIOMOL
Activator0529.4231126.395381.16586.1405110.3352124.4199134.8609111.812889.3843231.3882107.438329.4231QC'd by BIOMOL
Activator05143.615387.7329109.6233117.133130.2435108.007371.945131.4159458.2894127.4181102.4514143.6153QC'd by BIOMOL
Activator20.931115.76070Partial curve; high efficacy; poor fit-4.67924.50450.672852.682168.44282.30 0 0 0 0 0 0 0 1 0 057.3383156.9875210.0745196.4426169.3007145.4793168.5143122.6219177.1228240.8839147.192657.3383QC'd by BIOMOL
Inactive0-4.87923.51170.74543.7363121.376141 0 0 0 0 0 0 0 0 0 04.995969.848372.4018110.8591122.5541161.1408130.7083144.5237100.537122.353447.45634.9959QC'd by BIOMOL
Activator11.7704120.38030Partial curve; high efficacy; poor fit-4.92924.95490.6857256.5786136.19822.30 0 0 0 0 0 0 0 0 0 1129.6573124.8033153.6337147.2807166.633130.3024101.8421144.7083155.0295116.7688231.6699129.6573QC'd by BIOMOL
Activator05123.0403128.8699210.7699190.2566146.8479215.4495109.2714124.0291164.0907204.8081137.4596123.0403QC'd by BIOMOL
Activator3.722132.65680Complete curve; high efficacy; poor fit-5.42924.95490.427689.2254121.88221.30 1 0 0 0 0 0 0 0 0 0100.467287.1822158.1858123.8552104.2031121.5711143.849137.3495134.381992.833779.7182100.4672QC'd by BIOMOL
Activator1.4818129.40820Complete curve; high efficacy; poor fit-5.82920.90.7836.537165.94521.30 0 1 0 0 0 0 0 0 0 042.5687179.6537123.5264118.8734141.6283179.6193162.418995.5446129.667848.147154.875542.5687QC'd by BIOMOL
Activator0.066223.89990Complete curve; high efficacy; poor fit-7.17924.95490.3972157.0608133.16091.30 0 0 0 1 0 0 0 0 0 0156.4182131.6383146.4008133.9209120.0163196.9193161.7274189.7061147.8016155.1127132.5334156.4182QC'd by BIOMOL
Activator1.662639.6820Complete curve; high efficacy; poor fit-5.77924.95490.639368.8456108.52751.30 0 0 0 0 0 0 0 1 0 058.2968104.901585.3011114.5667123.321105.330499.8094125.775785.4017139.460580.25458.2968QC'd by BIOMOL
Activator7.4266132.89130Complete curve; high efficacy; poor fit-5.12921.96730.519645.9316178.8231.30 0 0 0 0 0 1 0 0 0 046.3684155.3315110.8327150.523132.3744223.2312259.9272370.7888225.3172120.431280.827846.3684QC'd by BIOMOL
Activator26.350664.97420Partial curve; high efficacy; poor fit-4.57924.50450.778765.5932130.56752.30 0 0 0 0 0 0 1 0 0 070.9665137.7579130.009140.9582142.8709108.0684128.1229122.723883.1025134.1418125.198170.9665QC'd by BIOMOL
Activator0.066242.96070Complete curve; high efficacy; poor fit-7.17924.95490.3774171.918128.95731.30 0 0 0 1 0 0 0 0 0 0186.2327131.3763114.3898169.2145100.0259417.4076185.7832137.3011196.8317196.7498128.9228186.2327QC'd by BIOMOL
Activator20.931357.07590Partial curve; high efficacy-4.67921.62660.9443496.1622139.08632.10 0 0 0 0 0 0 0 0 0 0450.0879120.9857123.3915150.1624127.9468154.6912129.5912127.2593186.5804191.2598245.2113450.0879QC'd by BIOMOL
Inactive0-5.52923.19250.683822.4254105.728640 0 0 0 0 1 0 0 0 0 026.507899.36974.653492.2028101.995999.5674165.511173.039787.234839.914614.050826.5078QC'd by BIOMOL
Activator4.685957.81330Complete curve; high efficacy; poor fit-5.32924.95490.7192154.795696.98231.30 0 0 1 0 0 0 0 0 0 0156.374697.7645116.034697.6905140.541797.0357110.7006102.992857.4166132.01153.4092156.3746QC'd by BIOMOL
Activator23.48541.33940Partial curve; high efficacy; poor fit-4.629210.526488.6415129.98092.30 1 0 0 0 0 0 0 0 0 097.9229133.620896.1141131.6403139.2531128.2736113.9247123.5101139.3218112.8157122.812997.9229QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Chlamydia trachomatis
External ID: CHEMBL3375714
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem. Lett.
Year: 2014
Volume: 24
Issue: 16
First Page: 3854
Last Page: 3860
DOI: 10.1016/j.bmcl.2014.06.056

Target ChEMBL ID: CHEMBL614606
ChEMBL Target Name: Chlamydia trachomatis
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
ActivityActive
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: BPDCN-CAL1
Protocol: A total of 500 exponentially growing Cal-1 cells were seeded per well in 5 uL of media (RPMI + Glutamine, without phenol red plus10% FBS and 1X Pen/Strep) into 1536-well solid white high base tissue culture treated Greiner One Bio Plates (789173-F), using a multidrop combi dispenser and a small sterile cassette. Compounds and controls totaling 23nL per well (negative control DMSO and positive control 9.2 uM Bortezomib-final) were immediately added to the plates using a 1536 head pin tool from Kalypsys. The plates were then covered with stainless steel gasket lids from Kalypsys and incubated for 48 hours at 37C under 95% relative humidity with 5% CO2. After 48 hours, the plates were removed and allowed to reach room temperature before 3 uL of Cell Titer Glo reagent (Promega) were added using an Aurora Flying Reagent Dispenser Bioraptor. The plates were then spun at 1000 rpms to remove bubbles and incubated for 15 minutes at room temperature before reading on a ViewLux using a luminescent filter with a 10 second exposure. The relative luciferase units were used to calculated percent activity using DMSO as 100% and Bortezomib as 0%.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001248848 uMActivity at 0.0002290931 uMActivity at 0.0004033765 uMActivity at 0.0007802858 uMActivity at 0.00138 uMActivity at 0.00235 uMActivity at 0.00481 uMActivity at 0.00706 uMActivity at 0.021 uMActivity at 0.031 uMActivity at 0.063 uMActivity at 0.111 uMActivity at 0.190 uMActivity at 0.335 uMActivity at 0.569 uMActivity at 1.004 uMActivity at 1.715 uMActivity at 3.506 uMActivity at 5.147 uMActivity at 15.26 uMActivity at 23.20 uMActivity at 45.80 uMActivity at 92.17 uMCompound QC
Activator0596.9812124.7788111.862799.1911109.8132115.8543122.7029124.978711.9636106.6618115.3296.9812QC'd by BIOMOL
Activator5.899218.55230Partial curve; high efficacy; poor fit-5.22921.59360.403698.2719116.82422.30 0 0 0 0 0 0 0 0 0 1112.1416116.3242116.0395124.1925105.021117.4347113.456126.6776109.8792109.999101.2806112.1416QC'd by BIOMOL
Activator0.0053140Complete curve; high efficacy; poor fit-8.27921.010.4672116.3066102.30661.30 0 0 0 0 0 0 0 0 0 0115.6225103.8066106.9288110.734112.8603113.7842118.7801117.453127.3511110.7768108.9356115.6225QC'd by BIOMOL
Inactive0-4.77922.72020.92567.4047112.261140 0 0 0 0 0 0 0 0 0 011.761291.0017111.0572112.5676117.0089126.6768110.9798121.4511106.8272107.246267.780211.7612QC'd by BIOMOL
Activator05113.2428112.6901103.509103.9003102.6066116.1617101.937105.552969.0952107.2108101.4004113.2428QC'd by BIOMOL
Inactive0-4.77923.1320.95268.0992113.058640 0 0 0 0 0 0 0 0 0 03.8949109.004119.742107.3798101.7335102.3462118.5813117.9993118.1915117.629571.87863.8949QC'd by BIOMOL
Inactive0-4.87921.75290.9755-3.302111.272940 0 0 0 0 0 0 0 0 0 09.2164111.826113.9215114.6486108.2664119.8515109.8219108.562295.88998.580743.56689.2164QC'd by BIOMOL
Activator16.626124.87630Partial curve; high efficacy; poor fit-4.77921.69240.347492.6528117.5292.30 0 0 0 0 0 0 0 0 0 095.2635108.3173105.9493113.7331109.0795117.0458137.3809129.6073122.6355108.5839108.131495.2635QC'd by BIOMOL
Activator05112.755117.1575116.8914112.2579112.3712121.4293115.3043115.3089107.1441121.4021110.4386112.755QC'd by BIOMOL
Inactive0-4.77922.18760.988510.0687113.747640 0 0 0 0 0 0 0 0 0 017.4423109.6122112.2788114.0082120.8283115.6809111.1114117.7232111.2532104.416766.142317.4423QC'd by BIOMOL
Inactive0-5.52924.50450.98317.5135117.599740 0 0 0 0 0 0 0 0 0 012.8583129.2377109.7349118.9217115.1912116.2997113.6696110.2515109.547223.646124.047512.8583QC'd by BIOMOL
Activator18.654846.19170Partial curve; high efficacy; poor fit-4.72924.50450.824765.8443112.03612.30 0 0 0 0 0 0 0 0 0 066.877599.5341112.8886111.9402121.8966115.7352104.7994116.4969106.3102117.563697.729766.8775QC'd by BIOMOL
Activator23.48562.95570Partial curve; high efficacy; poor fit-4.62924.0950.872243.341106.29672.30 0 0 0 0 0 0 0 0 0 048.3003107.43119.6331100.973899.0434113.2845112.3172103.148797.5313103.168398.057948.3003QC'd by BIOMOL
Inactive0-6.17920.90.991413.9467122.275740 0 0 0 0 0 0 0 0 0 016.0493121.1837125.2456121.294112.6383110.2161103.73666.18643.993533.762219.090416.0493QC'd by BIOMOL
Inactive0-4.72922.72020.979810.0162112.861540 0 0 0 0 0 0 0 0 0 012.0535113.9203107.621117.2056105.2005113.2177112.1472115.6483117.9416106.765277.54812.0535QC'd by BIOMOL
Activator10.490433.93550Complete curve; high efficacy; poor fit-4.97924.95490.813387.1253121.06091.30 0 0 0 0 0 0 0 0 0 087.3266113.333118.7195122.2141120.0529128.8421109.7936131.8841120.4381122.173491.04487.3266QC'd by BIOMOL
Activator05106.0617105.1595.4872110.3326113.665116.9489116.2338108.1254105.7991103.2361100.4977106.0617QC'd by BIOMOL
Inactive0-5.97921.10.982913.892796.744840 0 0 0 0 0 0 0 0 0 017.662101.545396.414590.127794.5053100.607678.9371.978945.24927.207613.540717.662QC'd by BIOMOL
Activator0.74275.43280Complete curve; high efficacy; poor fit-6.12924.95490.4642117.2092111.77641.30 0 0 0 0 0 0 0 0 0 1111.9075115.2092111.9615115.9844108.9243109.7763107.7652113.0327118.4395118.7792114.168111.9075QC'd by BIOMOL
Activator05109.5103113.4756109.9484115.0474114.0506116.6804107.3915105.6838121.9588114.747114.6431109.5103QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Staphylococcus aureus
External ID: CHEMBL1280819
Protocol: N/A
Comment: Journal: Antimicrob. Agents Chemother.
Year: 2008
Volume: 52
Issue: 8
First Page: 2923
Last Page: 2925
DOI: 10.1128/aac.00273-08

Target ChEMBL ID: CHEMBL352
ChEMBL Target Name: Staphylococcus aureus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard Value
FC=4.08
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase
External ID: CHEMBL664597
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1988
Volume: 31
Issue: 9
First Page: 1772
Last Page: 1778
DOI: 10.1021/jm00117a017

Target ChEMBL ID: CHEMBL2540
ChEMBL Target Name: UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
MIC=1ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase
External ID: CHEMBL664599
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1988
Volume: 31
Issue: 9
First Page: 1772
Last Page: 1778
DOI: 10.1021/jm00117a017

Target ChEMBL ID: CHEMBL2540
ChEMBL Target Name: UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
MIC=1ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase
External ID: CHEMBL858707
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1988
Volume: 31
Issue: 9
First Page: 1772
Last Page: 1778
DOI: 10.1021/jm00117a017

Target ChEMBL ID: CHEMBL2540
ChEMBL Target Name: UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
MIC=32ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase
External ID: CHEMBL664601
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1988
Volume: 31
Issue: 9
First Page: 1772
Last Page: 1778
DOI: 10.1021/jm00117a017

Target ChEMBL ID: CHEMBL2540
ChEMBL Target Name: UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
MIC=16ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase
External ID: CHEMBL664603
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1988
Volume: 31
Issue: 9
First Page: 1772
Last Page: 1778
DOI: 10.1021/jm00117a017

Target ChEMBL ID: CHEMBL2540
ChEMBL Target Name: UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
MIC=8ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase
External ID: CHEMBL664606
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1988
Volume: 31
Issue: 9
First Page: 1772
Last Page: 1778
DOI: 10.1021/jm00117a017

Target ChEMBL ID: CHEMBL2540
ChEMBL Target Name: UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
MIC>256ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Streptomyces scabiei
External ID: CHEMBL3079134
Protocol: N/A
Comment: Journal: J Pestic Sci
Year: 2003
Volume: 28
Issue: 2
First Page: 183
Last Page: 187
DOI: 10.1584/jpestics.28.183

Target ChEMBL ID: CHEMBL2366990
ChEMBL Target Name: Streptomyces scabiei
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
DIZNot Active
DIZNot Active
DIZNot Active
IZ=27mm
DIZNot Active
DIZNot Active
IZ=15mm
IZ=20mm
DIZNot Active
IZ=16mm
DIZNot Active
DIZNot Active
DIZNot Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase
External ID: CHEMBL664607
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1988
Volume: 31
Issue: 9
First Page: 1772
Last Page: 1778
DOI: 10.1021/jm00117a017

Target ChEMBL ID: CHEMBL2540
ChEMBL Target Name: UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
MIC=4ug.mL-1